--- title: "Peptide Directory | PepTracker Pro" url: https://peptrackerpro.com/peptides description: "Browse and search our comprehensive directory of peptides with evidence ratings, benefits, and safety information." lang: en --- Skip to main content **Educational information only.** This site does not provide medical advice. Read full disclaimer (https://peptrackerpro.com/disclaimer) # Peptide Directory Browse, search, and filter peptides by benefit, evidence level, and research status. 186 peptides found ### 5-Amino-1MQ Low Evidence A small molecule NNMT inhibitor studied for metabolic enhancement and fat cell reduction. Fat Loss: https://peptrackerpro.com/benefits/fat-loss Metabolism: https://peptrackerpro.com/benefits/metabolism Energy: https://peptrackerpro.com/benefits/energy View Details: https://peptrackerpro.com/peptides/5-amino-1mq \+ Compare: https://peptrackerpro.com/compare?select=5-amino-1mq Track in App: https://app.peptrackerpro.com/?add=5-amino-1mq ### Abaloparatide High Evidence Abaloparatide (Tymlos) is a synthetic 34-amino-acid analog of parathyroid hormone-related protein, PTHrP(1-34), engineered to bind the PTH1 receptor with a strong preference for its transient RG conformation rather than the long-lived R0 conformation favored by teriparatide. That receptor bias produces a shorter burst of signaling per injection - enough to drive osteoblast activity, but short enough to limit the bone resorption and calcium mobilization that follow a prolonged signal. In the 18-month Phase 3 ACTIVE trial in 2,463 postmenopausal women, abaloparatide 80 mcg daily reduced new morphometric vertebral fractures by 86% versus placebo, alongside significant reductions in nonvertebral, major osteoporotic and clinical fractures. The FDA approved Tymlos in April 2017; in December 2021 the osteosarcoma boxed warning and the two-year cumulative lifetime limit were both removed from the label. Bone Growth (https://peptrackerpro.com/benefits/bone-growth)Rare Disease Treatment (https://peptrackerpro.com/benefits/rare-disease-treatment)Hormone Support (https://peptrackerpro.com/benefits/hormone-support)Disease Modification (https://peptrackerpro.com/benefits/disease-modification)+1 more View Details: https://peptrackerpro.com/peptides/abaloparatide \+ Compare: https://peptrackerpro.com/compare?select=abaloparatide Track in App: https://app.peptrackerpro.com/?add=abaloparatide ### Abelacimab Medium Evidence Abelacimab (development code MAA868) is an investigational fully human monoclonal antibody being developed as a new kind of blood thinner (anticoagulant). It works by targeting Factor XI, a clotting protein that sits high in the coagulation 'cascade.' Abelacimab is described as a dual inhibitor: it binds the catalytic domain of Factor XI and locks the protein in its inactive (zymogen) shape, so it blocks both Factor XI itself and its activated form, Factor XIa, preventing the enzyme from being switched on by upstream triggers such as Factor XIIa or thrombin. The appeal of the Factor XI target is a long-standing observation in human biology: Factor XI contributes strongly to pathological clot formation (thrombosis) but only modestly to normal wound-sealing (hemostasis), so blocking it may prevent strokes and clots while causing much less bleeding than standard anticoagulants. Abelacimab is given as a once-monthly subcutaneous injection (with an intravenous loading option in some settings) and has a long duration of action. Its lead uses are stroke prevention in atrial fibrillation and the treatment and prevention of cancer-associated blood clots (venous thromboembolism, VTE). In the Phase 2b AZALEA-TIMI 71 trial, abelacimab reduced bleeding dramatically compared with the direct oral anticoagulant rivaroxaban - so much so that the study was stopped early - and it is now in Phase 3 development. Abelacimab was developed by Anthos Therapeutics, which Novartis originally helped launch and then reacquired in 2025. It is an investigational prescription biologic administered under medical supervision; it is not approved, and it is not a supplement, nootropic or research chemical. Cardiovascular: https://peptrackerpro.com/benefits/cardiovascular Hematology: https://peptrackerpro.com/benefits/hematology Disease Modification: https://peptrackerpro.com/benefits/disease-modification View Details: https://peptrackerpro.com/peptides/abelacimab \+ Compare: https://peptrackerpro.com/compare?select=abelacimab Track in App: https://app.peptrackerpro.com/?add=abelacimab ### ACCG-2671 Low Evidence An oral, once-daily small-molecule amylin receptor agonist in first-in-human Phase 1 testing for obesity — an early entrant in the race to make amylin biology available as a pill rather than an injection. Fat Loss: https://peptrackerpro.com/benefits/fat-loss Appetite Regulation: https://peptrackerpro.com/benefits/appetite-regulation Metabolism: https://peptrackerpro.com/benefits/metabolism View Details: https://peptrackerpro.com/peptides/accg-2671 \+ Compare: https://peptrackerpro.com/compare?select=accg-2671 Track in App: https://app.peptrackerpro.com/?add=accg-2671 ### AI-Discovered Antimicrobial Peptides Medium Evidence A new class of antimicrobial peptides discovered and optimized using artificial intelligence platforms, with over 79 active compounds identified from a catalog of 863,498 AI-predicted sequences showing efficacy against multidrug-resistant pathogens. Antimicrobial: https://peptrackerpro.com/benefits/antimicrobial View Details: https://peptrackerpro.com/peptides/ai-antimicrobial-peptides \+ Compare: https://peptrackerpro.com/compare?select=ai-antimicrobial-peptides Track in App: https://app.peptrackerpro.com/?add=ai-antimicrobial-peptides ### Aleniglipron Medium Evidence An oral non-peptide small-molecule GLP-1 receptor agonist achieving 16.3% placebo-adjusted weight loss at 44 weeks in Phase 2 ACCESS II, with Phase 3 on track for Q3 2026 after positive FDA end-of-Phase 2 feedback. Weight Management: https://peptrackerpro.com/benefits/weight-management Appetite Regulation: https://peptrackerpro.com/benefits/appetite-regulation Metabolism: https://peptrackerpro.com/benefits/metabolism Fat Loss: https://peptrackerpro.com/benefits/fat-loss View Details: https://peptrackerpro.com/peptides/aleniglipron \+ Compare: https://peptrackerpro.com/compare?select=aleniglipron Track in App: https://app.peptrackerpro.com/?add=aleniglipron ### ALV-100 Low Evidence A bifunctional GIPR-antagonist / GLP-1 receptor-agonist peptide in early clinical development for obesity, designed to improve the quality and durability of weight loss and long-term weight maintenance. Weight Management: https://peptrackerpro.com/benefits/weight-management Metabolism: https://peptrackerpro.com/benefits/metabolism Fat Loss: https://peptrackerpro.com/benefits/fat-loss Muscle Preservation: https://peptrackerpro.com/benefits/muscle-preservation View Details: https://peptrackerpro.com/peptides/alv-100 \+ Compare: https://peptrackerpro.com/compare?select=alv-100 Track in App: https://app.peptrackerpro.com/?add=alv-100 ### ALV-200 Low Evidence ALV-200 is Alveus Therapeutics' highly selective amylin receptor 3 (AMYR3) peptide agonist in IND-enabling development for obesity, designed to capture amylin's weight-loss and lean-mass-preserving benefits while avoiding the nausea and aversion tied to calcitonin-receptor activation. It is engineered for once-weekly dosing. View Details: https://peptrackerpro.com/peptides/alv-200 \+ Compare: https://peptrackerpro.com/compare?select=alv-200 Track in App: https://app.peptrackerpro.com/?add=alv-200 ### Amlitelimab High Evidence Amlitelimab (SAR445229, formerly KY1005) is a fully human, non-T-cell-depleting monoclonal antibody from Sanofi that blocks OX40 ligand (OX40L), a costimulatory signal that drives and sustains T-cell-mediated inflammation. Rather than neutralizing a single cytokine like IL-4/IL-13 (dupilumab) or IL-5 (depemokimab), amlitelimab acts upstream at the OX40-OX40L checkpoint to dampen a broad, memory-driven inflammatory program without depleting T cells. Its lead (anchor) indication is moderate-to-severe atopic dermatitis in people aged 12 and older, where a distinctive feature is very infrequent dosing: after a loading dose it is given subcutaneously as little as four times a year (every 12 weeks). In the Phase 3 program - COAST 1, COAST 2 and SHORE - amlitelimab met its primary endpoints with EASI-75 and vIGA-AD 0/1 responses that increased over time, though COAST 2's absolute response rates were more modest and some observers called that readout mixed. Amlitelimab is investigational and not yet approved by any regulator; Sanofi originally gained it through its ~$1.1B acquisition of Kymab in 2021. Inflammation: https://peptrackerpro.com/benefits/inflammation Immune Modulation: https://peptrackerpro.com/benefits/immune-modulation Skin: https://peptrackerpro.com/benefits/skin type-2-inflammation: https://peptrackerpro.com/benefits/type-2-inflammation View Details: https://peptrackerpro.com/peptides/amlitelimab \+ Compare: https://peptrackerpro.com/compare?select=amlitelimab Track in App: https://app.peptrackerpro.com/?add=amlitelimab ### Amycretin Medium Evidence A unimolecular GLP-1 and amylin receptor dual agonist in Phase 3 trials, available in both subcutaneous and oral formulations, with up to 22% weight loss in Phase 1b/2a. Weight Management (https://peptrackerpro.com/benefits/weight-management)Appetite Regulation (https://peptrackerpro.com/benefits/appetite-regulation)Metabolism (https://peptrackerpro.com/benefits/metabolism)Fat Loss (https://peptrackerpro.com/benefits/fat-loss)+1 more View Details: https://peptrackerpro.com/peptides/amycretin \+ Compare: https://peptrackerpro.com/compare?select=amycretin Track in App: https://app.peptrackerpro.com/?add=amycretin ### AOD-9604 Medium Evidence A modified fragment of human growth hormone studied for fat metabolism without growth-promoting effects. Fat Loss: https://peptrackerpro.com/benefits/fat-loss Metabolism: https://peptrackerpro.com/benefits/metabolism Joint Health: https://peptrackerpro.com/benefits/joint-health View Details: https://peptrackerpro.com/peptides/aod-9604 \+ Compare: https://peptrackerpro.com/compare?select=aod-9604 Track in App: https://app.peptrackerpro.com/?add=aod-9604 ### Apelin Medium Evidence An endogenous cardiovascular peptide that signals through the APJ receptor, studied for heart failure, cardiac repair, and cardioprotection with multiple synthetic analogs in clinical development. Recovery: https://peptrackerpro.com/benefits/recovery Inflammation: https://peptrackerpro.com/benefits/inflammation Energy: https://peptrackerpro.com/benefits/energy View Details: https://peptrackerpro.com/peptides/apelin \+ Compare: https://peptrackerpro.com/compare?select=apelin Track in App: https://app.peptrackerpro.com/?add=apelin ### Apitegromab Medium Evidence Apitegromab (SRK-015) is an investigational, fully human IgG4 monoclonal antibody developed by Scholar Rock that inhibits myostatin - the muscle-produced growth factor that limits skeletal-muscle mass - through a novel, muscle-selective mechanism. Rather than neutralizing mature, active myostatin (the approach of earlier failed inhibitors), apitegromab binds only the inactive precursor forms of the protein - promyostatin and latent myostatin - stored locally in muscle, and blocks their proteolytic conversion into the active ligand. Because it spares the closely related growth factors activin A, BMP9/10, and TGF-beta1, it aims to avoid the off-target effects (such as bleeding and vascular changes) that sank broad ActRII-pathway drugs. Apitegromab is the first muscle-targeted therapy to succeed in a pivotal Phase 3 trial in spinal muscular atrophy (SMA): in the 156-patient SAPPHIRE study of nonambulatory Type 2/3 patients aged 2-12 already on an SMN-directed therapy (nusinersen or risdiplam), adding apitegromab (10 or 20 mg/kg IV every 4 weeks) improved motor function by a pooled 1.8 points on the Hammersmith Functional Motor Scale Expanded (HFMSE) versus placebo at 12 months (p=0.019). Scholar Rock's initial Biologics License Application received an FDA Complete Response Letter in September 2025 tied solely to a third-party (Catalent Indiana) fill-finish manufacturing inspection - not to the drug's efficacy or safety - and the company resubmitted the BLA on March 31, 2026, with a PDUFA target action date of September 30, 2026. In parallel, apitegromab produced positive Phase 2 obesity data (EMBRAZE): added to tirzepatide over 24 weeks it preserved about 55% more lean mass (roughly 1.9 kg / 4.2 lb) than tirzepatide alone, positioning myostatin inhibition as a potential lean-mass-sparing partner for GLP-1-based weight loss. Metabolism: https://peptrackerpro.com/benefits/metabolism View Details: https://peptrackerpro.com/peptides/apitegromab \+ Compare: https://peptrackerpro.com/compare?select=apitegromab Track in App: https://app.peptrackerpro.com/?add=apitegromab ### Apraglutide Medium Evidence A long-acting, once-weekly glucagon-like peptide-2 (GLP-2) analog that boosts intestinal absorption in short bowel syndrome, aiming to reduce dependence on IV (parenteral) nutrition; in Phase 3 development with a confirmatory trial required by the FDA. Gut Health: https://peptrackerpro.com/benefits/gut-health View Details: https://peptrackerpro.com/peptides/apraglutide \+ Compare: https://peptrackerpro.com/compare?select=apraglutide Track in App: https://app.peptrackerpro.com/?add=apraglutide ### Ara-290 Medium Evidence A non-erythropoietic EPO analog studied for nerve repair and neuropathic pain conditions. Nerve Repair: https://peptrackerpro.com/benefits/nerve-repair Pain Relief: https://peptrackerpro.com/benefits/pain-relief Inflammation: https://peptrackerpro.com/benefits/inflammation Recovery: https://peptrackerpro.com/benefits/recovery View Details: https://peptrackerpro.com/peptides/ara-290 \+ Compare: https://peptrackerpro.com/compare?select=ara-290 Track in App: https://app.peptrackerpro.com/?add=ara-290 ### ARO-INHBE Low Evidence An investigational RNA-interference (RNAi) therapeutic from Arrowhead Pharmaceuticals designed to treat obesity by silencing a fat-storage gene in the liver. ARO-INHBE is a GalNAc-conjugated small interfering RNA (siRNA) that reduces hepatic expression of the INHBE gene and its secreted product, the hepatokine Activin E. INHBE is a genetically validated target: people who naturally carry rare loss-of-function variants in INHBE have a healthier (less abdominal) fat distribution and a lower risk of type 2 diabetes, suggesting that lowering Activin E with a drug could reproduce that protective metabolic profile. In an ongoing Phase 1/2a trial (AROINHBE-1001, NCT06700538), a single subcutaneous dose reduced serum Activin E by up to about 94%, and monotherapy reduced visceral fat by roughly 10-16% while modestly increasing lean tissue. Most strikingly, when added to the incretin drug tirzepatide in obese patients with type 2 diabetes, ARO-INHBE roughly doubled weight loss (-9.4% versus -4.8% at week 16) and roughly tripled reductions in visceral, total, and liver fat versus tirzepatide alone. These are small, early, interim results (as few as 3-4 participants per combination arm) - not proof of durable or long-term benefit. ARO-INHBE is investigational, is not approved anywhere, and is not a supplement or research chemical; it is studied only in clinical trials. Fat Loss (https://peptrackerpro.com/benefits/fat-loss)Body Composition (https://peptrackerpro.com/benefits/body-composition)Weight Management (https://peptrackerpro.com/benefits/weight-management)Metabolism (https://peptrackerpro.com/benefits/metabolism)+1 more View Details: https://peptrackerpro.com/peptides/aro-inhbe \+ Compare: https://peptrackerpro.com/compare?select=aro-inhbe Track in App: https://app.peptrackerpro.com/?add=aro-inhbe ### ASC30 Low Evidence An oral once-daily small-molecule GLP-1 receptor agonist developed by Ascletis Pharma, showing 5.4–7.7% placebo-adjusted weight loss at 13 weeks in Phase 2, with in vitro potency 2–3x greater than orforglipron. View Details: https://peptrackerpro.com/peptides/asc30 \+ Compare: https://peptrackerpro.com/compare?select=asc30 Track in App: https://app.peptrackerpro.com/?add=asc30 ### ASC35 Low Evidence A next-generation once-monthly GLP-1R/GIPR dual agonist peptide with a 14-day half-life (6-fold longer than tirzepatide) and 71% greater weight loss than tirzepatide in preclinical models. View Details: https://peptrackerpro.com/peptides/asc35 \+ Compare: https://peptrackerpro.com/compare?select=asc35 Track in App: https://app.peptrackerpro.com/?add=asc35 ### ASC36 Low Evidence A next-generation once-monthly amylin receptor agonist peptide with a 32-day half-life and 91% greater weight loss than petrelintide in preclinical models. IND filing expected Q2 2026. View Details: https://peptrackerpro.com/peptides/asc36 \+ Compare: https://peptrackerpro.com/compare?select=asc36 Track in App: https://app.peptrackerpro.com/?add=asc36 ### ASC37 Low Evidence A next-generation once-monthly GLP-1R/GIPR/GCGR triple peptide agonist with 5-fold greater potency than retatrutide and a 17-day half-life enabling monthly dosing. IND filing expected Q2 2026. View Details: https://peptrackerpro.com/peptides/asc37 \+ Compare: https://peptrackerpro.com/compare?select=asc37 Track in App: https://app.peptrackerpro.com/?add=asc37 ### ASC39 Low Evidence ASC39 is Ascletis Pharma's investigational once-daily oral small-molecule amylin-selective amylin receptor agonist for obesity. In head-to-head preclinical assays it matched Eli Lilly's injectable peptide eloralintide on amylin-receptor potency, selectivity over the calcitonin receptor, and weight loss in diet-induced obese rats. Ascletis plans to file a U.S. FDA IND for ASC39 - and for a fixed-dose combination with its oral GLP-1 agonist ASC30 - in the third quarter of 2026. View Details: https://peptrackerpro.com/peptides/asc39 \+ Compare: https://peptrackerpro.com/compare?select=asc39 Track in App: https://app.peptrackerpro.com/?add=asc39 ### ASC47 Low Evidence A first-in-class adipose-targeted thyroid hormone receptor beta (THRβ) agonist designed for muscle-preserving weight loss. Phase 1 data at ECO 2026 showed 111.8% greater weight loss when combined with semaglutide vs semaglutide alone. Weight Management: https://peptrackerpro.com/benefits/weight-management Fat Loss: https://peptrackerpro.com/benefits/fat-loss Metabolism: https://peptrackerpro.com/benefits/metabolism Muscle Preservation: https://peptrackerpro.com/benefits/muscle-preservation View Details: https://peptrackerpro.com/peptides/asc47 \+ Compare: https://peptrackerpro.com/compare?select=asc47 Track in App: https://app.peptrackerpro.com/?add=asc47 ### AT7687 Low Evidence A first-in-class GIPR antagonist peptide in early clinical development for obesity, designed as a once-weekly combination partner that adds weight loss and improves insulin sensitivity independent of appetite suppression. Weight Management: https://peptrackerpro.com/benefits/weight-management Metabolism: https://peptrackerpro.com/benefits/metabolism Fat Loss: https://peptrackerpro.com/benefits/fat-loss Glycemic Control: https://peptrackerpro.com/benefits/glycemic-control View Details: https://peptrackerpro.com/peptides/at7687 \+ Compare: https://peptrackerpro.com/compare?select=at7687 Track in App: https://app.peptrackerpro.com/?add=at7687 ### Atacicept High Evidence Atacicept (brand name Trutakna) is a recombinant soluble TACI-Fc fusion protein and the first dual BAFF/APRIL inhibitor approved for IgA nephropathy (IgAN). It fuses the extracellular ligand-binding domain of the TACI receptor to the Fc region of human IgG1, letting it soak up two B-cell survival cytokines at once - BAFF (B-cell activating factor) and APRIL (a proliferation-inducing ligand). By starving autoreactive B cells and plasma cells of both signals, atacicept lowers production of galactose-deficient IgA1 (Gd-IgA1), the abnormal antibody that drives immune-complex deposition and kidney injury in IgAN. It is given as a 150 mg once-weekly subcutaneous self-injection with an autoinjector at home. On July 7, 2026 the FDA granted atacicept accelerated approval (as Trutakna) to reduce proteinuria in adults with primary IgAN at risk of progression - the first and only BAFF-and-APRIL inhibitor cleared for the disease - based on the Phase 3 ORIGIN 3 trial (NCT04716231, 431 adults), in which it cut urine protein (UPCR) 46% from baseline and 42% versus placebo at week 36 (p<0.0001), reduced Gd-IgA1 by 68%, resolved hematuria in 81% of those with baseline blood in the urine, and produced serious adverse events in only 0.5% of patients (versus 5% on placebo). Originated at ZymoGenetics and developed by Merck KGaA (Merck Serono) before being out-licensed to Vera Therapeutics, atacicept sits alongside the anti-APRIL antibody sibeprenlimab and the engineered dual BAFF/APRIL inhibitor povetacicept in the fast-moving IgAN pipeline. renal: https://peptrackerpro.com/benefits/renal autoimmune: https://peptrackerpro.com/benefits/autoimmune Disease Modification: https://peptrackerpro.com/benefits/disease-modification B-cell-modulation: https://peptrackerpro.com/benefits/B-cell-modulation View Details: https://peptrackerpro.com/peptides/atacicept \+ Compare: https://peptrackerpro.com/compare?select=atacicept Track in App: https://app.peptrackerpro.com/?add=atacicept ### Avexitide Medium Evidence A first-in-class once-daily injectable GLP-1 receptor ANTAGONIST (exendin 9-39) from Amylyx for hyperinsulinemic hypoglycemia. The mirror image of GLP-1 agonists like semaglutide, it blocks GLP-1 to stop the insulin surges that cause post-bariatric hypoglycemia. Phase 3 LUCIDITY completed enrollment March 2026 with topline data expected Q3 2026. Glycemic Control: https://peptrackerpro.com/benefits/glycemic-control Metabolism: https://peptrackerpro.com/benefits/metabolism Rare Disease Treatment: https://peptrackerpro.com/benefits/rare-disease-treatment View Details: https://peptrackerpro.com/peptides/avexitide \+ Compare: https://peptrackerpro.com/compare?select=avexitide Track in App: https://app.peptrackerpro.com/?add=avexitide ### AZD6234 Medium Evidence AZD6234 is an investigational, long-acting selective amylin receptor agonist (SARA) from AstraZeneca, given once weekly by subcutaneous injection and developed for chronic weight management in adults with obesity or overweight. Amylin is a natural pancreatic hormone that works alongside insulin to signal fullness, slow stomach emptying and reduce food intake, and a wave of amylin-based drugs is being pursued as a better-tolerated alternative or partner to GLP-1 medicines such as semaglutide and tirzepatide. AZD6234 is engineered as a synthetic long-acting pramlintide analog whose balance of activity at the amylin receptor (AMY3R) versus the calcitonin receptor is tuned to mimic native amylin, and in animal studies it produced fat-selective weight loss while sparing lean mass and showed less nausea/aversion signaling than some rival approaches. It is now in Phase 2, including a factorial obesity study testing AZD6234 alone, AstraZeneca's GLP-1/glucagon dual agonist AZD9550 alone, and the two combined, versus placebo. AZD6234 is not approved by the FDA or any regulator for any use. weight-loss: https://peptrackerpro.com/benefits/weight-loss Appetite Regulation: https://peptrackerpro.com/benefits/appetite-regulation metabolic-health: https://peptrackerpro.com/benefits/metabolic-health View Details: https://peptrackerpro.com/peptides/azd6234 \+ Compare: https://peptrackerpro.com/compare?select=azd6234 Track in App: https://app.peptrackerpro.com/?add=azd6234 ### Barzolvolimab Medium Evidence Barzolvolimab (development code CDX-0159) is an investigational humanized IgG1 monoclonal antibody from Celldex Therapeutics that works by a mechanism new to allergy and dermatology: it depletes mast cells. It binds with high specificity to the KIT receptor (CD117), a receptor tyrosine kinase that mast cells depend on for their growth, survival and activation, and blocks KIT from being switched on by its natural ligand, stem cell factor (SCF). Because mast cells cannot survive without KIT signaling, blocking the receptor lowers mast-cell numbers throughout the body - an effect visible as a dose-dependent fall in blood tryptase (a mast-cell marker) and a drop in mast cells in the skin. Mast cells are the central drivers of chronic urticaria (chronic hives): when they release histamine and other mediators they cause the wheals, angioedema and itch that define the disease, so removing the cells themselves is a more upstream approach than blocking a single downstream signal. Barzolvolimab's lead program is chronic spontaneous urticaria (CSU) that no longer responds to antihistamines, where it is being tested in two large replicate Phase 3 trials, EMBARQ-CSU1 and EMBARQ-CSU2, which together enrolled 1,939 patients - the largest Phase 3 program ever run in antihistamine-refractory CSU - with topline results expected in late 2026 and a planned regulatory (BLA) filing in 2027. It has also shown strong Phase 2 results in the chronic inducible urticarias - cold urticaria and symptomatic dermographism - and is being explored in prurigo nodularis, atopic dermatitis and eosinophilic esophagitis. Barzolvolimab is an investigational biologic given by subcutaneous injection under clinical-trial or specialist supervision; it is not approved, and it is not a supplement, nootropic or research chemical. Inflammation: https://peptrackerpro.com/benefits/inflammation Immune Modulation: https://peptrackerpro.com/benefits/immune-modulation Skin: https://peptrackerpro.com/benefits/skin View Details: https://peptrackerpro.com/peptides/barzolvolimab \+ Compare: https://peptrackerpro.com/compare?select=barzolvolimab Track in App: https://app.peptrackerpro.com/?add=barzolvolimab ### Batoclimab High Evidence Batoclimab (development codes IMVT-1401, RVT-1401, HBM9161, HL161) is an investigational, fully human IgG1 monoclonal antibody that blocks the neonatal Fc receptor (FcRn), developed by Immunovant/Roivant (U.S. and Canada) and Harbour BioMed (Greater China) under license from HanAll Biopharma. It is not a small synthetic peptide but a full-length antibody given as a low-volume subcutaneous injection that patients can self-administer at home. Like the approved FcRn blockers efgartigimod, nipocalimab and rozanolixizumab, it lowers circulating IgG - including pathogenic autoantibodies - but it is best known for two things the others are not: it is the FcRn blocker that generated positive Phase 3 myasthenia gravis data yet was deliberately NOT filed for U.S. approval, and it is the one whose FcRn-mediated albumin recycling blockade produces a distinctive on-target signal of lowered serum albumin and raised LDL cholesterol - the exact liability that drove its makers to a re-engineered successor, IMVT-1402. Immune Modulation: https://peptrackerpro.com/benefits/immune-modulation Neuromuscular Function: https://peptrackerpro.com/benefits/neuromuscular-function Rare Disease Treatment: https://peptrackerpro.com/benefits/rare-disease-treatment Disease Modification: https://peptrackerpro.com/benefits/disease-modification View Details: https://peptrackerpro.com/peptides/batoclimab \+ Compare: https://peptrackerpro.com/compare?select=batoclimab Track in App: https://app.peptrackerpro.com/?add=batoclimab ### Berobenatide Medium Evidence A once-monthly injectable GLP-1 receptor agonist developed by Pfizer (acquired from Metsera), showing 12.3% placebo-adjusted weight loss in Phase 2b trials with a tolerability profile comparable to weekly semaglutide. View Details: https://peptrackerpro.com/peptides/berobenatide \+ Compare: https://peptrackerpro.com/compare?select=berobenatide Track in App: https://app.peptrackerpro.com/?add=berobenatide ### BI 3034701 Low Evidence A potential first-in-class triple GLP-1, GIP, and NPY2 receptor agonist peptide entering Phase 2 development mid-2026 for obesity, developed by Boehringer Ingelheim using Gubra-discovered technology. Weight Management: https://peptrackerpro.com/benefits/weight-management Appetite Regulation: https://peptrackerpro.com/benefits/appetite-regulation Fat Loss: https://peptrackerpro.com/benefits/fat-loss Metabolism: https://peptrackerpro.com/benefits/metabolism View Details: https://peptrackerpro.com/peptides/bi-3034701 \+ Compare: https://peptrackerpro.com/compare?select=bi-3034701 Track in App: https://app.peptrackerpro.com/?add=bi-3034701 ### Bimagrumab Medium Evidence An anti-activin type II receptor antibody that promotes fat loss while preserving lean muscle mass, studied in combination with GLP-1 agonists for obesity. Fat Loss (https://peptrackerpro.com/benefits/fat-loss)Muscle Preservation (https://peptrackerpro.com/benefits/muscle-preservation)Weight Management (https://peptrackerpro.com/benefits/weight-management)Body Composition (https://peptrackerpro.com/benefits/body-composition)+1 more View Details: https://peptrackerpro.com/peptides/bimagrumab \+ Compare: https://peptrackerpro.com/compare?select=bimagrumab Track in App: https://app.peptrackerpro.com/?add=bimagrumab ### BPC-157 Medium Evidence A pentadecapeptide derived from human gastric juice, studied for tissue repair and gut-protective properties. Recovery (https://peptrackerpro.com/benefits/recovery)Gut Health (https://peptrackerpro.com/benefits/gut-health)Wound Healing (https://peptrackerpro.com/benefits/wound-healing)Joint Health (https://peptrackerpro.com/benefits/joint-health)+2 more View Details: https://peptrackerpro.com/peptides/bpc-157 \+ Compare: https://peptrackerpro.com/compare?select=bpc-157 Track in App: https://app.peptrackerpro.com/?add=bpc-157 ### BPC/TB500 Blend Low Evidence A combined formulation of BPC-157 and TB-500, the two most commonly paired tissue repair peptides. Recovery: https://peptrackerpro.com/benefits/recovery Wound Healing: https://peptrackerpro.com/benefits/wound-healing Inflammation: https://peptrackerpro.com/benefits/inflammation Joint Health: https://peptrackerpro.com/benefits/joint-health View Details: https://peptrackerpro.com/peptides/bpc-tb500-blend \+ Compare: https://peptrackerpro.com/compare?select=bpc-tb500-blend Track in App: https://app.peptrackerpro.com/?add=bpc-tb500-blend ### BRP Low Evidence A 12-amino-acid peptide discovered via AI that suppresses appetite by acting on the hypothalamus, without nausea or muscle loss observed in animal models. Appetite Regulation: https://peptrackerpro.com/benefits/appetite-regulation Weight Management: https://peptrackerpro.com/benefits/weight-management Fat Loss: https://peptrackerpro.com/benefits/fat-loss Metabolism: https://peptrackerpro.com/benefits/metabolism View Details: https://peptrackerpro.com/peptides/brp \+ Compare: https://peptrackerpro.com/compare?select=brp Track in App: https://app.peptrackerpro.com/?add=brp ### BT-11 High Evidence A synthetic 15-amino-acid peptide derived from the IL-10 receptor alpha chain, granted FDA breakthrough therapy status for systemic lupus erythematosus (SLE) after Phase III trial success. Inflammation: https://peptrackerpro.com/benefits/inflammation Immune Modulation: https://peptrackerpro.com/benefits/immune-modulation View Details: https://peptrackerpro.com/peptides/bt-11 \+ Compare: https://peptrackerpro.com/compare?select=bt-11 Track in App: https://app.peptrackerpro.com/?add=bt-11 ### BWB3054 Low Evidence A GIP/glucagon dual agonist that achieves weight loss comparable to retatrutide without GLP-1 receptor activity, potentially eliminating GI side effects. Published in Molecular Metabolism (April 2026). View Details: https://peptrackerpro.com/peptides/bwb3054 \+ Compare: https://peptrackerpro.com/compare?select=bwb3054 Track in App: https://app.peptrackerpro.com/?add=bwb3054 ### Cagrilintide High Evidence A long-acting amylin analog studied for appetite regulation; NDA filed for CagriSema (cagrilintide + semaglutide) combination in December 2025, with FDA review expected in 2026. Weight Management: https://peptrackerpro.com/benefits/weight-management Appetite Regulation: https://peptrackerpro.com/benefits/appetite-regulation Metabolism: https://peptrackerpro.com/benefits/metabolism View Details: https://peptrackerpro.com/peptides/cagrilintide \+ Compare: https://peptrackerpro.com/compare?select=cagrilintide Track in App: https://app.peptrackerpro.com/?add=cagrilintide ### CagriSema High Evidence A fixed-dose combination of cagrilintide (amylin analog) and semaglutide (GLP-1 agonist) studied for enhanced weight loss through dual hormonal pathways. View Details: https://peptrackerpro.com/peptides/cagrisema \+ Compare: https://peptrackerpro.com/compare?select=cagrisema Track in App: https://app.peptrackerpro.com/?add=cagrisema ### CAP-GDF15 Low Evidence A newly discovered 12-amino acid anorexigenic peptide derived from the GDF15 prepropeptide region, representing a novel appetite-suppression pathway. Appetite Regulation: https://peptrackerpro.com/benefits/appetite-regulation Weight Management: https://peptrackerpro.com/benefits/weight-management Metabolism: https://peptrackerpro.com/benefits/metabolism View Details: https://peptrackerpro.com/peptides/cap-gdf15 \+ Compare: https://peptrackerpro.com/compare?select=cap-gdf15 Track in App: https://app.peptrackerpro.com/?add=cap-gdf15 ### CAQK Medium Evidence A brain-targeting tetrapeptide studied for neuroprotection and targeted drug delivery to injured brain and spinal cord tissue. Neuroprotection: https://peptrackerpro.com/benefits/neuroprotection Cognition: https://peptrackerpro.com/benefits/cognition Oncology: https://peptrackerpro.com/benefits/oncology Inflammation: https://peptrackerpro.com/benefits/inflammation View Details: https://peptrackerpro.com/peptides/caqk \+ Compare: https://peptrackerpro.com/compare?select=caqk Track in App: https://app.peptrackerpro.com/?add=caqk ### Cerebrolysin Medium Evidence A porcine brain-derived peptide mixture approved in some countries for stroke recovery and neurodegenerative conditions. Neuroprotection: https://peptrackerpro.com/benefits/neuroprotection Cognition: https://peptrackerpro.com/benefits/cognition Recovery: https://peptrackerpro.com/benefits/recovery View Details: https://peptrackerpro.com/peptides/cerebrolysin \+ Compare: https://peptrackerpro.com/compare?select=cerebrolysin Track in App: https://app.peptrackerpro.com/?add=cerebrolysin ### CJC-1295 Medium Evidence A growth hormone releasing hormone analog studied for stimulating growth hormone secretion. Muscle Growth (https://peptrackerpro.com/benefits/muscle-growth)Fat Loss (https://peptrackerpro.com/benefits/fat-loss)Recovery (https://peptrackerpro.com/benefits/recovery)Sleep (https://peptrackerpro.com/benefits/sleep)+1 more View Details: https://peptrackerpro.com/peptides/cjc-1295 \+ Compare: https://peptrackerpro.com/compare?select=cjc-1295 Track in App: https://app.peptrackerpro.com/?add=cjc-1295 ### CJC-1295 (DAC) Medium Evidence A long-acting GHRH analog with an extended half-life due to its Drug Affinity Complex modification. View Details: https://peptrackerpro.com/peptides/cjc-1295-dac \+ Compare: https://peptrackerpro.com/compare?select=cjc-1295-dac Track in App: https://app.peptrackerpro.com/?add=cjc-1295-dac ### Conveglipron Low Evidence An oral, once-daily small-molecule GLP-1 receptor agonist (developmental code HDM1002) from Huadong Medicine, in clinical trials for obesity and type 2 diabetes — part of the next wave of GLP-1 'pills' competing with orforglipron. View Details: https://peptrackerpro.com/peptides/conveglipron \+ Compare: https://peptrackerpro.com/compare?select=conveglipron Track in App: https://app.peptrackerpro.com/?add=conveglipron ### Cotadutide Medium Evidence A once-daily GLP-1/glucagon dual receptor agonist studied for MASH, obesity, and type 2 diabetes with demonstrated liver fat reduction and antifibrotic activity. Weight Management: https://peptrackerpro.com/benefits/weight-management Metabolism: https://peptrackerpro.com/benefits/metabolism Fat Loss: https://peptrackerpro.com/benefits/fat-loss Appetite Regulation: https://peptrackerpro.com/benefits/appetite-regulation View Details: https://peptrackerpro.com/peptides/cotadutide \+ Compare: https://peptrackerpro.com/compare?select=cotadutide Track in App: https://app.peptrackerpro.com/?add=cotadutide ### CT-388 Medium Evidence An investigational once-weekly subcutaneous dual GLP-1 and GIP receptor agonist from Roche/Genentech (acquired with Carmot Therapeutics for ~$2.7 billion; Roche code RO7795068). CT-388 is engineered as a 'signal-biased' agonist: it potently activates both incretin receptors but recruits little or no beta-arrestin, which is expected to reduce receptor internalization and desensitization and thereby prolong pharmacological activity. In a Phase 1b study it produced ~18.8% placebo-adjusted weight loss at 24 weeks, and in the Phase 2 CT388-103 dose-finding trial (469 adults with obesity/overweight) it delivered a placebo-adjusted mean weight loss of 22.5% at 48 weeks (efficacy estimand; 18.3% treatment-regimen estimand) at the top 24 mg dose, without reaching a plateau. Roche advanced CT-388 into Phase 3 in the first half of 2026, positioning it as a late-entrant competitor to tirzepatide (Zepbound) with a potentially differentiated biased-signaling mechanism. Weight Management: https://peptrackerpro.com/benefits/weight-management Glycemic Control: https://peptrackerpro.com/benefits/glycemic-control View Details: https://peptrackerpro.com/peptides/ct-388 \+ Compare: https://peptrackerpro.com/compare?select=ct-388 Track in App: https://app.peptrackerpro.com/?add=ct-388 ### CX11 Medium Evidence CX11 is an investigational once-daily oral small-molecule GLP-1 receptor agonist (Corxel/Vincentage) that produced up to 11.5% weight loss at 36 weeks in a 246-patient U.S. Phase 2 obesity trial, with a notably low 12-16% vomiting rate and no hepatic safety signal; global Phase 3 is planned after positive China Phase 3 results. View Details: https://peptrackerpro.com/peptides/cx11 \+ Compare: https://peptrackerpro.com/compare?select=cx11 Track in App: https://app.peptrackerpro.com/?add=cx11 ### DA-1726 Low Evidence A novel once-weekly GLP-1/glucagon dual receptor agonist showing rapid weight loss in Phase 1 trials with preserved lean body mass and direct liver benefits. Weight Management: https://peptrackerpro.com/benefits/weight-management Fat Loss: https://peptrackerpro.com/benefits/fat-loss Metabolism: https://peptrackerpro.com/benefits/metabolism Appetite Regulation: https://peptrackerpro.com/benefits/appetite-regulation View Details: https://peptrackerpro.com/peptides/da-1726 \+ Compare: https://peptrackerpro.com/compare?select=da-1726 Track in App: https://app.peptrackerpro.com/?add=da-1726 ### Danuglipron Medium Evidence An oral small-molecule GLP-1 receptor agonist discontinued by Pfizer in 2026 after a potential drug-induced liver injury signal, despite showing meaningful weight loss in Phase 2b. View Details: https://peptrackerpro.com/peptides/danuglipron \+ Compare: https://peptrackerpro.com/compare?select=danuglipron Track in App: https://app.peptrackerpro.com/?add=danuglipron ### Dapiglutide Medium Evidence A long-acting, once-weekly dual GLP-1 and GLP-2 receptor agonist peptide (Zealand Pharma) developed for obesity, uniquely pairing GLP-1-driven weight loss with GLP-2 activation intended to improve intestinal barrier function and reduce obesity-related low-grade inflammation; development was paused in November 2025. Weight Management: https://peptrackerpro.com/benefits/weight-management Metabolism: https://peptrackerpro.com/benefits/metabolism Gut Health: https://peptrackerpro.com/benefits/gut-health Inflammation: https://peptrackerpro.com/benefits/inflammation View Details: https://peptrackerpro.com/peptides/dapiglutide \+ Compare: https://peptrackerpro.com/compare?select=dapiglutide Track in App: https://app.peptrackerpro.com/?add=dapiglutide ### Davunetide Low Evidence An eight-amino-acid ADNP-derived peptide studied for microtubule stabilization, tau-related neuroprotection, and rare ADNP syndrome. Cognition: https://peptrackerpro.com/benefits/cognition Neuroprotection: https://peptrackerpro.com/benefits/neuroprotection View Details: https://peptrackerpro.com/peptides/davunetide \+ Compare: https://peptrackerpro.com/compare?select=davunetide Track in App: https://app.peptrackerpro.com/?add=davunetide ### Depemokimab High Evidence Depemokimab (brand name Exdensur; nonproprietary name depemokimab-ulaa; development code GSK3511294) is a humanized, affinity-matured IgG1 monoclonal antibody that blocks interleukin-5 (IL-5), the master cytokine for eosinophils - the white blood cells that drive type 2 (eosinophilic) inflammation in severe asthma and related diseases. Developed by GSK, it is the first ultra-long-acting IL-5 biologic, engineered both for very high IL-5 binding affinity (roughly 29-fold more potent than mepolizumab in vitro) and with a triple-amino-acid 'YTE' modification in its Fc region that extends its half-life, enabling a fixed 100 mg subcutaneous injection just twice a year (once every 26 weeks). By neutralizing IL-5 before it can reach the IL-5 receptor on eosinophils, depemokimab lowers blood and airway eosinophils and reduces the flare-ups (exacerbations) that define severe eosinophilic asthma. In the pivotal Phase 3 SWIFT-1 and SWIFT-2 trials, twice-yearly depemokimab cut annualized asthma exacerbations by roughly half versus placebo over 52 weeks (58% in SWIFT-1, 48% in SWIFT-2), with a pooled ~72% reduction in exacerbations requiring hospitalization or emergency care. On the strength of those data, the U.S. FDA approved Exdensur in December 2025 as an add-on maintenance treatment for severe asthma with an eosinophilic phenotype in patients aged 12 and older, and it is also being developed - and, in China, approved - for chronic rhinosinusitis with nasal polyps (CRSwNP). Depemokimab is a prescription biologic given under medical care; it is not a supplement, nootropic, or research chemical. anti-inflammatory: https://peptrackerpro.com/benefits/anti-inflammatory respiratory: https://peptrackerpro.com/benefits/respiratory Immune Modulation: https://peptrackerpro.com/benefits/immune-modulation type-2-inflammation: https://peptrackerpro.com/benefits/type-2-inflammation View Details: https://peptrackerpro.com/peptides/depemokimab \+ Compare: https://peptrackerpro.com/compare?select=depemokimab Track in App: https://app.peptrackerpro.com/?add=depemokimab ### Difelikefalin High Evidence Difelikefalin (Korsuva in the U.S., Kapruvia in Europe) is a synthetic tetrapeptide built entirely from D-amino acids - D-Phe-D-Phe-D-Leu-D-Lys capped with a 4-aminopiperidine-4-carboxylic acid - that acts as a selective agonist at the kappa opioid receptor. Its defining property is what it cannot do: the molecule is hydrophilic and bulky enough that it does not meaningfully cross the blood-brain barrier, so it reaches kappa receptors on peripheral sensory nerve endings, keratinocytes and immune cells while leaving the central kappa receptors that produce dysphoria and hallucinations largely untouched. It has no activity at the mu opioid receptor, so it carries neither euphoria nor respiratory depression. In the Phase 3 KALM-1 and KALM-2 trials in hemodialysis patients with moderate-to-severe chronic-kidney-disease-associated pruritus, roughly 40-51% of difelikefalin-treated patients achieved a clinically meaningful (>=3-point) reduction on the 10-point Worst Itching Intensity NRS at 12 weeks versus roughly 20-28% on placebo. The FDA approved intravenous difelikefalin in August 2021; the EU approved it as Kapruvia in April 2022. Pain Relief (https://peptrackerpro.com/benefits/pain-relief)Inflammation (https://peptrackerpro.com/benefits/inflammation)Skin (https://peptrackerpro.com/benefits/skin)Disease Modification (https://peptrackerpro.com/benefits/disease-modification)+1 more View Details: https://peptrackerpro.com/peptides/difelikefalin \+ Compare: https://peptrackerpro.com/compare?select=difelikefalin Track in App: https://app.peptrackerpro.com/?add=difelikefalin ### Dihexa Low Evidence A hexapeptide analog studied for cognitive enhancement via hepatocyte growth factor pathway activation. Cognition: https://peptrackerpro.com/benefits/cognition Neuroprotection: https://peptrackerpro.com/benefits/neuroprotection Anti-Aging: https://peptrackerpro.com/benefits/anti-aging View Details: https://peptrackerpro.com/peptides/dihexa \+ Compare: https://peptrackerpro.com/compare?select=dihexa Track in App: https://app.peptrackerpro.com/?add=dihexa ### Donidalorsen High Evidence An FDA-approved RNA-targeted therapy that prevents hereditary angioedema (HAE) attacks by turning down production of a single blood protein rather than blocking it after it forms. Donidalorsen (brand name Dawnzera) is a GalNAc-conjugated antisense oligonucleotide (ASO) taken up by liver cells, where it binds the messenger RNA for prekallikrein (the gene KLKB1) and triggers its degradation, lowering circulating prekallikrein. Because prekallikrein sits at the top of the kallikrein-kinin cascade that generates bradykinin - the peptide that drives the swelling of HAE - reducing it prevents the runaway bradykinin surges responsible for painful, sometimes life-threatening attacks. It was approved by the U.S. FDA on August 21, 2025 as the first and only RNA-targeted prophylactic medicine for HAE, for routine prevention of attacks in adults and children aged 12 and older. It is given as an 80 mg subcutaneous self-injection by autoinjector once every four weeks, with the option to move to once every eight weeks in well-controlled patients. In the pivotal Phase 3 OASIS-HAE trial, donidalorsen reduced monthly HAE attacks by about 81% versus placebo over 24 weeks, and in the OASISplus switch study most patients who moved from other long-term prophylaxis preferred donidalorsen. Donidalorsen is a prescription biologic developed by Ionis Pharmaceuticals and administered under specialist care - not a supplement or research chemical. Immune Modulation: https://peptrackerpro.com/benefits/immune-modulation Rare Disease Treatment: https://peptrackerpro.com/benefits/rare-disease-treatment View Details: https://peptrackerpro.com/peptides/donidalorsen \+ Compare: https://peptrackerpro.com/compare?select=donidalorsen Track in App: https://app.peptrackerpro.com/?add=donidalorsen ### DSIP Low Evidence A neuropeptide studied for its role in sleep regulation and stress modulation. Sleep: https://peptrackerpro.com/benefits/sleep Mood: https://peptrackerpro.com/benefits/mood Anxiety Relief: https://peptrackerpro.com/benefits/anxiety-relief Pain Relief: https://peptrackerpro.com/benefits/pain-relief View Details: https://peptrackerpro.com/peptides/dsip \+ Compare: https://peptrackerpro.com/compare?select=dsip Track in App: https://app.peptrackerpro.com/?add=dsip ### Ecnoglutide High Evidence A cAMP signaling-biased GLP-1 receptor agonist approved in China for chronic weight management, with Phase 3 data showing up to 15.4% weight loss. Weight Management: https://peptrackerpro.com/benefits/weight-management Fat Loss: https://peptrackerpro.com/benefits/fat-loss Appetite Regulation: https://peptrackerpro.com/benefits/appetite-regulation Metabolism: https://peptrackerpro.com/benefits/metabolism View Details: https://peptrackerpro.com/peptides/ecnoglutide \+ Compare: https://peptrackerpro.com/compare?select=ecnoglutide Track in App: https://app.peptrackerpro.com/?add=ecnoglutide ### Efgartigimod High Evidence Efgartigimod (efgartigimod alfa, brand names Vyvgart intravenous and Vyvgart Hytrulo subcutaneous) is a first-in-class antagonist of the neonatal Fc receptor (FcRn) developed by argenx as ARGX-113. It is not a small synthetic peptide but an engineered fragment of the human immunoglobulin G1 (IgG1) antibody - specifically the Fc portion that normally binds FcRn - modified with argenx's ABDEG technology to bind FcRn with much higher affinity than natural IgG at both neutral and acidic pH. FcRn is the salvage receptor that rescues circulating IgG from lysosomal degradation and recycles it back into the blood, giving antibodies their long half-life. By outcompeting endogenous IgG for FcRn, efgartigimod blocks that recycling and drives rapid clearance of IgG - including the pathogenic autoantibodies that cause many autoimmune diseases - typically lowering total IgG by roughly 60-70% within weeks, without reducing IgM, IgA, or albumin. It was the first FcRn blocker ever approved: FDA-approved in December 2021 (Vyvgart IV) for acetylcholine-receptor-antibody-positive generalized myasthenia gravis (gMG) on the strength of the Phase 3 ADAPT trial, followed by a subcutaneous co-formulation with recombinant hyaluronidase (Vyvgart Hytrulo) for gMG in 2023 and for chronic inflammatory demyelinating polyneuropathy (CIDP) in 2024. In May 2026 the FDA expanded the gMG label to all serotypes - including AChR-antibody-negative (seronegative) patients - based on the Phase 3 ADAPT SERON trial, making efgartigimod the first and only therapy approved across every gMG antibody subtype. It is being studied in a broad set of other IgG-driven autoimmune diseases, including primary immune thrombocytopenia, myositis, Sjogren's disease, bullous pemphigoid, and lupus nephritis. View Details: https://peptrackerpro.com/peptides/efgartigimod \+ Compare: https://peptrackerpro.com/compare?select=efgartigimod Track in App: https://app.peptrackerpro.com/?add=efgartigimod ### Efimosfermin Alfa Medium Evidence Efimosfermin alfa (development code BOS-580) is an investigational, long-acting, engineered analog of the metabolic hormone fibroblast growth factor 21 (FGF21) being developed by GSK - which acquired the molecule from Boston Pharmaceuticals in May 2025 for $1.2 billion upfront and up to $800 million in milestones (potential ~$2 billion total) - for steatotic liver disease, principally metabolic dysfunction-associated steatohepatitis (MASH, formerly NASH). Its defining feature is a very long half-life engineered to allow once-monthly subcutaneous dosing - the least frequent schedule among the leading FGF21 analogs, contrasting with the once-weekly or every-two-weeks dosing of efruxifermin (an Fc-FGF21 fusion) and pegozafermin (a glycoPEGylated FGF21). Like the rest of the class, it activates FGF receptors (FGFR1c/2c/3c) together with the co-receptor beta-Klotho to cut liver fat, improve insulin sensitivity, lower triglycerides, and drive direct anti-inflammatory and anti-fibrotic effects in the liver. In a 24-week Phase 2 trial in biopsy-confirmed F2-F3 MASH, once-monthly efimosfermin achieved at least one-stage fibrosis improvement without worsening of MASH in about 45% of patients and MASH resolution without worsening of fibrosis in about 68%, both significantly better than placebo (published in The Lancet, 2025). It holds FDA Breakthrough Therapy designation and EMA PRIME (Priority Medicines) status for MASH, and has advanced into the Phase 3 ZENITH program (ZENITH-1 and ZENITH-2 in F2-F3 MASH), with a Phase 3 program in compensated (F4) MASH cirrhosis also underway; GSK has guided to a first potential launch around 2029. View Details: https://peptrackerpro.com/peptides/efimosfermin \+ Compare: https://peptrackerpro.com/compare?select=efimosfermin Track in App: https://app.peptrackerpro.com/?add=efimosfermin ### Efinopegdutide Medium Evidence Efinopegdutide (MK-6024, formerly HM12525A and JNJ-64565111) is an investigational once-weekly subcutaneous dual agonist of the GLP-1 and glucagon receptors being developed by Merck for metabolic dysfunction-associated steatohepatitis (MASH, formerly NASH) and steatotic liver disease. It is a synthetic oxyntomodulin-based peptide - a modified GLP-1/glucagon dual-agonist sequence conjugated to a human IgG4 Fc fragment through a 10 kDa polyethylene glycol linker using Hanmi Pharmaceutical's LAPSCovery half-life-extension platform, which stretches dosing to once weekly. The design pairs the GLP-1 arm (appetite suppression, glycemic control, weight loss) with a glucagon arm that raises energy expenditure and acts directly on the liver to burn hepatic fat - the feature that sets it apart from pure GLP-1 drugs. In the head-to-head Phase 2a trial in NAFLD (Journal of Hepatology, 2023), efinopegdutide 10 mg cut liver fat content by 72.7% at 24 weeks versus 42.3% for semaglutide 1 mg, with two-thirds of efinopegdutide recipients falling below the 5% liver-fat threshold that defines a normal liver. Merck holds FDA Fast Track designation for the MASH program and is running Phase 2b studies plus a dedicated trial in compensated cirrhosis due to steatohepatitis; the earlier type 2 diabetes and obesity indications were discontinued in favor of the liver focus. Metabolism (https://peptrackerpro.com/benefits/metabolism)Liver Health (https://peptrackerpro.com/benefits/liver-health)Weight Management (https://peptrackerpro.com/benefits/weight-management)Disease Modification (https://peptrackerpro.com/benefits/disease-modification)+1 more View Details: https://peptrackerpro.com/peptides/efinopegdutide \+ Compare: https://peptrackerpro.com/compare?select=efinopegdutide Track in App: https://app.peptrackerpro.com/?add=efinopegdutide ### Efocipegtrutide Medium Evidence Efocipegtrutide (Hanmi code HM15211) is an investigational, long-acting, once-weekly GLP-1/GIP/glucagon 'triple' receptor agonist being developed primarily for metabolic dysfunction-associated steatohepatitis (MASH, formerly NASH) rather than obesity alone. It is built on Hanmi's LAPSCovery platform as a chemical conjugate of a chimeric tri-agonist peptide (TA15211) fused to a human IgG4 Fc fragment, which extends its half-life via FcRn-mediated recycling and enables weekly subcutaneous dosing. By adding glucagon-receptor activation to the GLP-1/GIP dual mechanism, efocipegtrutide is designed to combine appetite suppression and glycemic control with increased energy expenditure and direct hepatic anti-steatotic, anti-inflammatory, and anti-fibrotic effects. In a Phase 1b/2a study in obese subjects with non-alcoholic fatty liver disease, 12 weeks of treatment reduced liver fat by roughly 20% to 59% (dose-dependent, MRI-PDFF) versus about 6% on placebo. It has FDA Fast Track designation for MASH and orphan-drug designations from the FDA and EMA for primary biliary cholangitis (PBC), primary sclerosing cholangitis (PSC), and idiopathic pulmonary fibrosis (IPF). The 52-week adaptive Phase 2 HM-TRIA-201 study (NCT04505436) in biopsy-confirmed MASH with fibrosis is the pivotal read the field is watching. Liver Health: https://peptrackerpro.com/benefits/liver-health Weight Management: https://peptrackerpro.com/benefits/weight-management Glycemic Control: https://peptrackerpro.com/benefits/glycemic-control Metabolism: https://peptrackerpro.com/benefits/metabolism View Details: https://peptrackerpro.com/peptides/efocipegtrutide \+ Compare: https://peptrackerpro.com/compare?select=efocipegtrutide Track in App: https://app.peptrackerpro.com/?add=efocipegtrutide ### Efpeglenatide High Evidence A once-weekly, long-acting GLP-1 receptor agonist from Hanmi Pharmaceutical built on a different molecular backbone than semaglutide or liraglutide: instead of a modified human GLP-1, efpeglenatide uses exendin-4 - the naturally DPP-4-resistant GLP-1 mimic first found in Gila monster venom - fused to a fragment of a human antibody (an IgG4 Fc) through a small polyethylene-glycol (mini-PEG) linker using Hanmi's LAPSCOVERY half-life-extension platform. That design lets one subcutaneous injection lower blood sugar, curb appetite and reduce body weight for a full week. Efpeglenatide is best known for the landmark AMPLITUDE-O cardiovascular outcomes trial (NEJM 2021), in which 4,076 people with type 2 diabetes and cardiovascular or kidney disease had a 27% lower rate of major adverse cardiovascular events (MACE hazard ratio 0.73) and a 32% lower rate of a composite kidney outcome (hazard ratio 0.68) versus placebo - the first cardiovascular outcomes win for an exendin-based GLP-1 and one of the clearest kidney signals in the class, with benefit seen regardless of whether patients were also taking an SGLT2 inhibitor. Originally licensed to Sanofi and then returned to Hanmi in 2020, efpeglenatide is now being advanced primarily for obesity and overweight, with a Phase 3 program that has completed enrollment and a targeted first launch in South Korea in the second half of 2026. It is an investigational (not yet approved) prescription medicine, not a supplement or research chemical. Weight Management: https://peptrackerpro.com/benefits/weight-management Glycemic Control: https://peptrackerpro.com/benefits/glycemic-control Cardiovascular: https://peptrackerpro.com/benefits/cardiovascular Kidney Health: https://peptrackerpro.com/benefits/kidney-health View Details: https://peptrackerpro.com/peptides/efpeglenatide \+ Compare: https://peptrackerpro.com/compare?select=efpeglenatide Track in App: https://app.peptrackerpro.com/?add=efpeglenatide ### Efruxifermin Medium Evidence Efruxifermin (development codes EFX, AKR-001; originally AMG 876) is an investigational, once-weekly, subcutaneously injected analog of the metabolic hormone fibroblast growth factor 21 (FGF21) being developed by Akero Therapeutics for metabolic dysfunction-associated steatohepatitis (MASH, formerly NASH), including both pre-cirrhotic fibrosis and compensated (F4) cirrhosis. It is a bivalent Fc-FGF21 fusion protein - two engineered FGF21 sequences fused to a human immunoglobulin (IgG1) Fc domain - a design distinct from the glycoPEGylation used by its main FGF21-class rival, pegozafermin. The Fc fusion extends the very short half-life of native FGF21 to support once-weekly dosing while preserving agonism at FGF receptors (FGFR1c/2c/3c) together with the co-receptor beta-Klotho. In the 96-week Phase 2b HARMONY trial in biopsy-confirmed F2-F3 MASH, at least a one-stage improvement in fibrosis without worsening of MASH was reached by about 75% of patients on 50 mg and 46% on 28 mg versus 24% on placebo (published in The Lancet, August 2025). In the Phase 2b SYMMETRY trial in compensated MASH cirrhosis, about 39% of 50 mg patients with paired week-96 biopsies achieved reversal of cirrhosis without worsening of MASH versus 15% on placebo (published in the New England Journal of Medicine). Efruxifermin holds FDA Breakthrough Therapy designation and has advanced into the Phase 3 SYNCHRONY program (SYNCHRONY Histology in F2-F3 MASH, SYNCHRONY Outcomes in F4 compensated cirrhosis, and SYNCHRONY Real-World in non-invasively diagnosed MASH/MASLD, whose double-blind portion completed enrollment with safety results expected in 2026). View Details: https://peptrackerpro.com/peptides/efruxifermin \+ Compare: https://peptrackerpro.com/compare?select=efruxifermin Track in App: https://app.peptrackerpro.com/?add=efruxifermin ### Efzofitimod Medium Evidence A first-in-class, intravenous immunomodulatory fusion peptide derived from histidyl-tRNA synthetase that selectively binds neuropilin-2 (NRP2) to dampen inflammation in the lung; in Phase 3 development for pulmonary sarcoidosis, an interstitial lung disease. Inflammation: https://peptrackerpro.com/benefits/inflammation Immune Support: https://peptrackerpro.com/benefits/immune-support View Details: https://peptrackerpro.com/peptides/efzofitimod \+ Compare: https://peptrackerpro.com/compare?select=efzofitimod Track in App: https://app.peptrackerpro.com/?add=efzofitimod ### Elecoglipron Medium Evidence An investigational, once-daily oral small-molecule GLP-1 receptor agonist from AstraZeneca that delivered up to about 11.8% weight loss at 36 weeks in people with obesity or overweight and strong blood-sugar control in type 2 diabetes, and is now advancing into a large Phase 3 program. Unlike semaglutide and tirzepatide - which are injectable peptides - elecoglipron is a small chemical molecule that mimics the natural GLP-1 hormone at its receptor in the gut and hypothalamus, so it can be taken as a pill with no food or fasting restrictions and is easier and cheaper to manufacture at global scale than peptide drugs. In the Phase 2b VISTA trial (n=310) the 75 mg once-daily regimen produced an average body-weight reduction of 10.5% at 26 weeks (vs 0.6% placebo) that had not plateaued, reaching about 11.8% at 36 weeks, with up to 88.8% of participants achieving at least 5% weight loss. In the Phase 2b SOLSTICE trial in type 2 diabetes (n=404) the 75 mg regimen cut HbA1c by 1.9% at 26 weeks (vs 0.2% placebo) - with roughly 90% of participants reaching an HbA1c below 7% - alongside 7.7% weight loss, numerically ahead of an open-label oral semaglutide 14 mg comparator arm. Side effects were the familiar GLP-1 class gastrointestinal symptoms (nausea, constipation, diarrhea, vomiting), mostly mild to moderate, with infrequent discontinuations and no liver safety signals. Both trials were presented at the 2026 American Diabetes Association (ADA) Scientific Sessions in New Orleans and published simultaneously in The Lancet, and on June 8, 2026 AstraZeneca announced elecoglipron would move into an extensive Phase 3 program - the EMBOLD obesity trials and the ELUMINATE type 2 diabetes trials (including combination with dapagliflozin), plus cardiovascular and kidney outcome studies. Elecoglipron is an investigational prescription-stage medicine - it is not approved anywhere and is not a supplement or research chemical. Weight Management (https://peptrackerpro.com/benefits/weight-management)Appetite Regulation (https://peptrackerpro.com/benefits/appetite-regulation)Metabolism (https://peptrackerpro.com/benefits/metabolism)Glycemic Control (https://peptrackerpro.com/benefits/glycemic-control)+1 more View Details: https://peptrackerpro.com/peptides/elecoglipron \+ Compare: https://peptrackerpro.com/compare?select=elecoglipron Track in App: https://app.peptrackerpro.com/?add=elecoglipron ### Eloralintide Medium Evidence A selective, long-acting amylin receptor agonist in Phase 3 trials for obesity, offering a GLP-1-independent weight loss mechanism with up to 20.1% weight loss in Phase 2. View Details: https://peptrackerpro.com/peptides/eloralintide \+ Compare: https://peptrackerpro.com/compare?select=eloralintide Track in App: https://app.peptrackerpro.com/?add=eloralintide ### Enicepatide Medium Evidence An investigational once-weekly, cAMP signal-biased dual GLP-1/GIP receptor agonist from Roche/Genentech that produced up to ~22.5% placebo-adjusted weight loss at 48 weeks in Phase 2 and is advancing to Phase 3 for obesity. Weight Management (https://peptrackerpro.com/benefits/weight-management)Metabolism (https://peptrackerpro.com/benefits/metabolism)Fat Loss (https://peptrackerpro.com/benefits/fat-loss)Appetite Regulation (https://peptrackerpro.com/benefits/appetite-regulation)+1 more View Details: https://peptrackerpro.com/peptides/enicepatide \+ Compare: https://peptrackerpro.com/compare?select=enicepatide Track in App: https://app.peptrackerpro.com/?add=enicepatide ### Enlicitide High Evidence An oral PCSK9 inhibitor peptide that reduced LDL cholesterol by 57% in Phase 3 trials — matching injectable monoclonal antibodies in efficacy while offering once-daily pill convenience. Cardiovascular: https://peptrackerpro.com/benefits/cardiovascular Cholesterol Management: https://peptrackerpro.com/benefits/cholesterol-management Metabolism: https://peptrackerpro.com/benefits/metabolism View Details: https://peptrackerpro.com/peptides/enlicitide \+ Compare: https://peptrackerpro.com/compare?select=enlicitide Track in App: https://app.peptrackerpro.com/?add=enlicitide ### Epithalon Low Evidence A tetrapeptide studied for its potential to activate telomerase and influence biological aging markers. Longevity: https://peptrackerpro.com/benefits/longevity Anti-Aging: https://peptrackerpro.com/benefits/anti-aging Sleep: https://peptrackerpro.com/benefits/sleep Immune Support: https://peptrackerpro.com/benefits/immune-support View Details: https://peptrackerpro.com/peptides/epithalon \+ Compare: https://peptrackerpro.com/compare?select=epithalon Track in App: https://app.peptrackerpro.com/?add=epithalon ### Eplontersen High Evidence An approved, once-monthly, self-administered subcutaneous GalNAc-conjugated antisense oligonucleotide (ASO) from Ionis and AstraZeneca that treats transthyretin-mediated (ATTR) amyloidosis by lowering the liver's production of transthyretin (TTR). Transthyretin is a liver-made transport protein that can misfold and deposit as amyloid in nerves and the heart; eplontersen is a short synthetic strand of chemically modified DNA/RNA that binds TTR messenger RNA and directs its enzymatic (RNase H1) degradation before the protein is made, cutting circulating TTR by roughly 80%. A triantennary N-acetylgalactosamine (GalNAc) tag delivers it to liver cells, allowing a low-dose 45 mg injection just once a month via autoinjector or pre-filled syringe. Marketed as Wainua (US) and Wainzua (EU), it was FDA-approved in December 2023 for the polyneuropathy of hereditary ATTR amyloidosis (ATTRv-PN) on the strength of the NEURO-TTRansform trial, and is now approved in more than 20 countries. Eplontersen is the antisense (ASO) counterpart to the siRNA drug vutrisiran (Amvuttra): both silence TTR, and both were tested in ATTR cardiomyopathy - but where vutrisiran's HELIOS-B trial succeeded on top of a stabilizer background, eplontersen's much larger CARDIO-TTRansform cardiomyopathy trial missed its primary endpoint in July 2026, with a benefit seen only in the prespecified monotherapy subgroup. It is a GalNAc-ASO sibling of Ionis's olezarsen and pelacarsen and the second-generation successor to the earlier, non-GalNAc TTR antisense drug inotersen (Tegsedi). Neuroprotection: https://peptrackerpro.com/benefits/neuroprotection Disease Modification: https://peptrackerpro.com/benefits/disease-modification Rare Disease Treatment: https://peptrackerpro.com/benefits/rare-disease-treatment Cardiovascular: https://peptrackerpro.com/benefits/cardiovascular View Details: https://peptrackerpro.com/peptides/eplontersen \+ Compare: https://peptrackerpro.com/compare?select=eplontersen Track in App: https://app.peptrackerpro.com/?add=eplontersen ### Felzartamab Medium Evidence Felzartamab (development codes MOR202/MOR03087, and TJ202 in Greater China) is an investigational fully human IgG1 monoclonal antibody that targets CD38, a protein carried at high density on the antibody-producing plasma cells and plasmablasts of the immune system. Rather than blocking a single circulating antibody or downstream mediator, felzartamab depletes the very cells that manufacture pathogenic (disease-causing) antibodies, with the logic that shutting down the factory stops the harmful antibodies at their source. CD38 antibodies are an established drug class in cancer (daratumumab and isatuximab are approved for multiple myeloma), and felzartamab is being repurposed to switch off the autoantibody-driven immune attack behind several serious kidney diseases. It is given as an intravenous infusion in defined treatment courses (for example, a roughly five- to nine-dose regimen) rather than indefinitely. Felzartamab has become one of the most closely watched agents in nephrology because it is advancing through three separate Phase 3 programs in rare, antibody-mediated kidney diseases: IgA nephropathy (IgAN), primary membranous nephropathy (PMN), and late antibody-mediated rejection (AMR) of a transplanted kidney. It originated at MorphoSys AG, was licensed to Human Immunology Biosciences (HI-Bio), which Biogen acquired in 2024, and Biogen consolidated the Greater China rights from TJ Biopharma in 2026. It holds FDA Breakthrough Therapy designation in primary membranous nephropathy. Felzartamab is an investigational prescription biologic administered under medical supervision; it is not approved for kidney disease, and it is not a supplement, nootropic or research chemical. View Details: https://peptrackerpro.com/peptides/felzartamab \+ Compare: https://peptrackerpro.com/compare?select=felzartamab Track in App: https://app.peptrackerpro.com/?add=felzartamab ### Fitusiran High Evidence An FDA-approved RNA-interference (RNAi) therapy for hemophilia that works by lowering a natural blood-thinning protein rather than replacing a missing clotting factor. Fitusiran (brand name Qfitlia) is a GalNAc-conjugated small interfering RNA (siRNA) that is taken up by liver cells and silences the gene for antithrombin, the body's main brake on clotting. By reducing antithrombin, fitusiran 'rebalances' hemostasis so that people with hemophilia A or B can generate enough thrombin to form stable clots and bleed less often. It was approved by the U.S. FDA on March 28, 2025 - the first siRNA (RNAi) therapy for hemophilia and the first medicine that treats hemophilia by lowering antithrombin - for routine prophylaxis in adults and children aged 12 and older with hemophilia A or B, with or without factor VIII or IX inhibitors. A key practical advantage is that it is given as an infrequent subcutaneous injection (starting once every two months, as few as about six injections per year) and works regardless of hemophilia type or inhibitor status. In the pivotal Phase 3 ATLAS trials, fitusiran reduced the annualized bleeding rate by about 90% versus on-demand treatment. Because lowering antithrombin shifts the clotting balance, fitusiran carries a boxed warning for thrombotic (clotting) events and gallbladder disease, and it is now dosed to a target antithrombin level (15-35%) to reduce clot risk. Fitusiran is a prescription biologic administered under medical supervision - not a supplement or research chemical. Hematology: https://peptrackerpro.com/benefits/hematology Rare Disease Treatment: https://peptrackerpro.com/benefits/rare-disease-treatment View Details: https://peptrackerpro.com/peptides/fitusiran \+ Compare: https://peptrackerpro.com/compare?select=fitusiran Track in App: https://app.peptrackerpro.com/?add=fitusiran ### FOXO4-DRI Low Evidence A senolytic peptide designed to selectively clear senescent cells by disrupting FOXO4-p53 interaction. Longevity: https://peptrackerpro.com/benefits/longevity Anti-Aging: https://peptrackerpro.com/benefits/anti-aging Skin: https://peptrackerpro.com/benefits/skin View Details: https://peptrackerpro.com/peptides/foxo4-dri \+ Compare: https://peptrackerpro.com/compare?select=foxo4-dri Track in App: https://app.peptrackerpro.com/?add=foxo4-dri ### Frexalimab High Evidence Frexalimab (SAR441344) is an investigational second-generation, fully human monoclonal antibody from Sanofi that blocks CD40 ligand (CD40L, also called CD154), a costimulatory 'second signal' that helps activate B cells, T cells and antigen-presenting cells and drives adaptive autoimmunity. Rather than depleting immune cells, frexalimab interrupts the CD40-CD40L checkpoint upstream - a mechanism related to but distinct from the OX40-OX40L blockade of amlitelimab. Its lead indication is relapsing multiple sclerosis (RMS), with a second program in nonrelapsing secondary progressive MS (nrSPMS). In the Phase 2 relapsing-MS trial (NCT04879628, published in the New England Journal of Medicine in 2024), frexalimab cut the number of new gadolinium-enhancing brain lesions at week 12 by 89% (higher-dose IV arm) and 79% (lower-dose subcutaneous arm) versus placebo, and open-label extensions out to two and three years show that disease control and reductions in neurofilament light have been sustained. Crucially, frexalimab is engineered so its Fc region does not activate platelets, which is designed to avoid the thromboembolic complications that halted first-generation anti-CD40L antibodies decades ago. It is now in the Phase 3 FREXALT (relapsing MS, versus teriflunomide) and FREVIVA (nrSPMS, versus placebo) trials, with additional Phase 2 programs in type 1 diabetes (FABULINUS) and systemic lupus erythematosus; a Sjogren's syndrome study was discontinued in 2024 after it fell short on efficacy. Frexalimab is investigational and not approved by any regulator. Immune Modulation: https://peptrackerpro.com/benefits/immune-modulation Inflammation: https://peptrackerpro.com/benefits/inflammation autoimmune: https://peptrackerpro.com/benefits/autoimmune Disease Modification: https://peptrackerpro.com/benefits/disease-modification View Details: https://peptrackerpro.com/peptides/frexalimab \+ Compare: https://peptrackerpro.com/compare?select=frexalimab Track in App: https://app.peptrackerpro.com/?add=frexalimab ### Garadacimab High Evidence Garadacimab (brand name Andembry; garadacimab-gxii) is a first-in-class, fully human monoclonal antibody that inhibits activated Factor XII (FXIIa), used once monthly to prevent attacks of hereditary angioedema (HAE). HAE is a rare, potentially life-threatening genetic disease in which unchecked activation of the plasma contact system floods the body with bradykinin, causing sudden, recurrent swelling of the skin, gut and airway. FXIIa is the very first enzyme in that contact-system cascade, so garadacimab shuts the pathway off at its source - blocking FXIIa before it can activate plasma kallikrein and generate the bradykinin that drives swelling. It is given as a 400 mg subcutaneous loading dose followed by 200 mg once-monthly subcutaneous self-injection with an autoinjector (an injection that takes about 15 seconds), making it the only HAE prophylaxis that targets FXIIa and offers once-monthly dosing for all eligible patients from the start. Approval rests on the pivotal Phase 3 VANGUARD trial (NCT04656418), a global, randomized, double-blind, placebo-controlled study of 64 patients aged 12 and older, in which garadacimab cut the monthly HAE attack rate by a least-squares mean of 89.2% versus placebo (median reduction greater than 99%) over the 6-month treatment period, with 62% of treated patients attack-free; the results were published in The Lancet in 2023. The FDA approved Andembry on June 16, 2025 to prevent HAE attacks in people aged 12 and older, following European (February 2025), Australian and Canadian approvals. On July 27, 2026 CSL reported positive top-line Phase 3b results in children aged 2 to 11, with most young participants remaining attack-free over a 12-month treatment period, supporting a planned expanded pediatric filing. Discovered and optimized at CSL's Bio21 research site and developed by CSL Behring, garadacimab sits alongside the antisense prekallikrein-lowering drug donidalorsen, the anti-plasma-kallikrein antibody lanadelumab, the oral kallikrein inhibitor berotralstat and C1-esterase-inhibitor concentrates in the modern HAE prevention toolkit. immunology: https://peptrackerpro.com/benefits/immunology rare-disease: https://peptrackerpro.com/benefits/rare-disease hereditary-angioedema: https://peptrackerpro.com/benefits/hereditary-angioedema attack-prevention: https://peptrackerpro.com/benefits/attack-prevention View Details: https://peptrackerpro.com/peptides/garadacimab \+ Compare: https://peptrackerpro.com/compare?select=garadacimab Track in App: https://app.peptrackerpro.com/?add=garadacimab ### Garetosmab Medium Evidence Garetosmab (REGN2477) is Regeneron's investigational fully human anti-activin A monoclonal antibody. In the Phase 3 OPTIMA trial in adults with the ultra-rare bone disease fibrodysplasia ossificans progressiva (FOP), it cut new heterotopic bone lesions by ~90-94% and reduced new-lesion volume by >99% versus placebo; its BLA was accepted for FDA Priority Review with an August 2026 target action date. The same activin A blockade also makes garetosmab the muscle-preserving partner to trevogrumab and semaglutide in the Phase 2 COURAGE obesity program. Bone Growth (https://peptrackerpro.com/benefits/bone-growth)Rare Disease Treatment (https://peptrackerpro.com/benefits/rare-disease-treatment)Muscle Preservation (https://peptrackerpro.com/benefits/muscle-preservation)Body Composition (https://peptrackerpro.com/benefits/body-composition)+1 more View Details: https://peptrackerpro.com/peptides/garetosmab \+ Compare: https://peptrackerpro.com/compare?select=garetosmab Track in App: https://app.peptrackerpro.com/?add=garetosmab ### GDF-15 Receptor Agonists Medium Evidence A new class of peptide-based weight loss therapeutics that act through the GFRAL/RET receptor in the brainstem, representing a non-GLP-1 mechanism for appetite suppression and energy expenditure regulation. Weight Management (https://peptrackerpro.com/benefits/weight-management)Appetite Regulation (https://peptrackerpro.com/benefits/appetite-regulation)Fat Loss (https://peptrackerpro.com/benefits/fat-loss)Metabolism (https://peptrackerpro.com/benefits/metabolism)+1 more View Details: https://peptrackerpro.com/peptides/gdf15-agonists \+ Compare: https://peptrackerpro.com/compare?select=gdf15-agonists Track in App: https://app.peptrackerpro.com/?add=gdf15-agonists ### GEP-44 Low Evidence A novel triple agonist peptide targeting GLP-1 and peptide YY receptors Y1 and Y2, designed to suppress appetite and improve glycemic control while avoiding GI side effects common to first-generation GLP-1 drugs. View Details: https://peptrackerpro.com/peptides/gep-44 \+ Compare: https://peptrackerpro.com/compare?select=gep-44 Track in App: https://app.peptrackerpro.com/?add=gep-44 ### GHK-Cu High Evidence A naturally occurring copper-binding peptide studied for skin regeneration, wound healing, and anti-aging effects. Skin (https://peptrackerpro.com/benefits/skin)Anti-Aging (https://peptrackerpro.com/benefits/anti-aging)Wound Healing (https://peptrackerpro.com/benefits/wound-healing)Hair Growth (https://peptrackerpro.com/benefits/hair-growth)+2 more View Details: https://peptrackerpro.com/peptides/ghk-cu \+ Compare: https://peptrackerpro.com/compare?select=ghk-cu Track in App: https://app.peptrackerpro.com/?add=ghk-cu ### GHRP-2 Medium Evidence A synthetic hexapeptide growth hormone secretagogue studied for its potent stimulation of growth hormone release via the ghrelin receptor. Hormone Support (https://peptrackerpro.com/benefits/hormone-support)Recovery (https://peptrackerpro.com/benefits/recovery)Muscle Growth (https://peptrackerpro.com/benefits/muscle-growth)Sleep (https://peptrackerpro.com/benefits/sleep)+1 more View Details: https://peptrackerpro.com/peptides/ghrp-2 \+ Compare: https://peptrackerpro.com/compare?select=ghrp-2 Track in App: https://app.peptrackerpro.com/?add=ghrp-2 ### GHRP-6 Medium Evidence A growth hormone secretagogue that also stimulates appetite through ghrelin receptor activation. Muscle Growth: https://peptrackerpro.com/benefits/muscle-growth Fat Loss: https://peptrackerpro.com/benefits/fat-loss Recovery: https://peptrackerpro.com/benefits/recovery Appetite Regulation: https://peptrackerpro.com/benefits/appetite-regulation View Details: https://peptrackerpro.com/peptides/ghrp-6 \+ Compare: https://peptrackerpro.com/compare?select=ghrp-6 Track in App: https://app.peptrackerpro.com/?add=ghrp-6 ### Glepaglutide Medium Evidence A long-acting glucagon-like peptide-2 (GLP-2) analog given by once- or twice-weekly subcutaneous injection that helps the gut absorb more nutrients in short bowel syndrome, reducing dependence on IV (parenteral) nutrition. View Details: https://peptrackerpro.com/peptides/glepaglutide \+ Compare: https://peptrackerpro.com/compare?select=glepaglutide Track in App: https://app.peptrackerpro.com/?add=glepaglutide ### GLOW Low Evidence A multi-peptide blend of BPC-157, TB-500, and GHK-Cu formulated for tissue repair and skin rejuvenation. Recovery: https://peptrackerpro.com/benefits/recovery Wound Healing: https://peptrackerpro.com/benefits/wound-healing Skin: https://peptrackerpro.com/benefits/skin Anti-Aging: https://peptrackerpro.com/benefits/anti-aging View Details: https://peptrackerpro.com/peptides/glow \+ Compare: https://peptrackerpro.com/compare?select=glow Track in App: https://app.peptrackerpro.com/?add=glow ### GLP-1-GIP-Lani (Quintuple Agonist) Low Evidence A first-in-class peptide-drug conjugate that simultaneously activates five metabolic receptors (GLP-1R, GIPR, PPARα, PPARγ, PPARδ), published in Nature in April 2026 with preclinical results surpassing tirzepatide and triple agonists. View Details: https://peptrackerpro.com/peptides/glp1-gip-lani \+ Compare: https://peptrackerpro.com/compare?select=glp1-gip-lani Track in App: https://app.peptrackerpro.com/?add=glp1-gip-lani ### HCG High Evidence A hormone used clinically for fertility treatment and testosterone support during hormone replacement therapy. Hormone Support: https://peptrackerpro.com/benefits/hormone-support Fertility: https://peptrackerpro.com/benefits/fertility Sexual Health: https://peptrackerpro.com/benefits/sexual-health View Details: https://peptrackerpro.com/peptides/hcg \+ Compare: https://peptrackerpro.com/compare?select=hcg Track in App: https://app.peptrackerpro.com/?add=hcg ### HMG High Evidence A gonadotropin preparation containing FSH and LH, used in fertility protocols for both men and women. Fertility: https://peptrackerpro.com/benefits/fertility Hormone Support: https://peptrackerpro.com/benefits/hormone-support View Details: https://peptrackerpro.com/peptides/hmg \+ Compare: https://peptrackerpro.com/compare?select=hmg Track in App: https://app.peptrackerpro.com/?add=hmg ### HRS9531 (KAI-9531) Medium Evidence An investigational once-weekly injectable dual GLP-1/GIP receptor agonist - the same peptide class as tirzepatide (Zepbound/Mounjaro) - developed by China's Jiangsu Hengrui Pharmaceuticals as HRS9531 and licensed to U.S.-based Kailera Therapeutics, which is developing it globally (outside Greater China) as KAI-9531. In the pivotal 48-week Phase 3 GEMINI-1 trial in China (NCT06396429; 567 adults with obesity or overweight without diabetes), once-weekly HRS9531 produced mean weight loss of about 17.4-19.2% at the 4 mg and 6 mg doses (per-protocol/hypothetical estimand) versus roughly 1.4% for placebo, with about 44% of 6 mg patients losing at least 20% of body weight and broad improvements in blood pressure, lipids, insulin resistance, and inflammation (hsCRP). An earlier Phase 2 trial reported about 23.6% mean weight loss at the higher 8 mg dose by week 36 with no plateau. Hengrui has submitted a marketing application to China's NMPA for chronic weight management, and Kailera began a global Phase 3 program (KAI-9531) evaluating higher maintenance doses (8 mg and 10 mg) and longer treatment by late 2025. HRS9531/KAI-9531 is investigational, is not approved outside of any regulatory review in China, and is not a supplement or research chemical; it is studied only in clinical trials. Weight Management (https://peptrackerpro.com/benefits/weight-management)Fat Loss (https://peptrackerpro.com/benefits/fat-loss)Body Composition (https://peptrackerpro.com/benefits/body-composition)Metabolism (https://peptrackerpro.com/benefits/metabolism)+1 more View Details: https://peptrackerpro.com/peptides/hrs9531 \+ Compare: https://peptrackerpro.com/compare?select=hrs9531 Track in App: https://app.peptrackerpro.com/?add=hrs9531 ### Humanin Low Evidence An endogenous mitochondrial-derived peptide studied for neuroprotection, cellular stress resistance, and longevity, whose blood levels fall with age and are elevated in centenarians. Longevity (https://peptrackerpro.com/benefits/longevity)Anti-Aging (https://peptrackerpro.com/benefits/anti-aging)Neuroprotection (https://peptrackerpro.com/benefits/neuroprotection)Metabolism (https://peptrackerpro.com/benefits/metabolism)+1 more View Details: https://peptrackerpro.com/peptides/humanin \+ Compare: https://peptrackerpro.com/compare?select=humanin Track in App: https://app.peptrackerpro.com/?add=humanin ### Icotrokinra (ICOTYDE) High Evidence The first FDA-approved targeted oral macrocyclic peptide — an IL-23 receptor antagonist for moderate-to-severe plaque psoriasis, marking a new era for oral peptide therapeutics. Skin: https://peptrackerpro.com/benefits/skin Inflammation: https://peptrackerpro.com/benefits/inflammation Immune Support: https://peptrackerpro.com/benefits/immune-support View Details: https://peptrackerpro.com/peptides/icotrokinra \+ Compare: https://peptrackerpro.com/compare?select=icotrokinra Track in App: https://app.peptrackerpro.com/?add=icotrokinra ### IGF-1 LR3 Medium Evidence A modified form of IGF-1 with extended half-life, studied for muscle growth and tissue development. Muscle Growth: https://peptrackerpro.com/benefits/muscle-growth Recovery: https://peptrackerpro.com/benefits/recovery Fat Loss: https://peptrackerpro.com/benefits/fat-loss View Details: https://peptrackerpro.com/peptides/igf-1-lr3 \+ Compare: https://peptrackerpro.com/compare?select=igf-1-lr3 Track in App: https://app.peptrackerpro.com/?add=igf-1-lr3 ### IGF-DES Low Evidence A truncated form of IGF-1 with high potency and rapid local activity at the site of administration. Muscle Growth: https://peptrackerpro.com/benefits/muscle-growth Recovery: https://peptrackerpro.com/benefits/recovery View Details: https://peptrackerpro.com/peptides/igf-des \+ Compare: https://peptrackerpro.com/compare?select=igf-des Track in App: https://app.peptrackerpro.com/?add=igf-des ### IMVT-1402 Medium Evidence IMVT-1402 (international nonproprietary name imeroprubart; originally HL161ANS) is Immunovant/Roivant's investigational, next-generation, fully human IgG1 monoclonal antibody that blocks the neonatal Fc receptor (FcRn). It is a re-engineered successor to batoclimab, built to keep batoclimab's deep IgG-lowering while removing that molecule's defining liability: because FcRn recycles serum albumin as well as IgG, first-generation FcRn blockers reproducibly lowered albumin and raised LDL cholesterol, and IMVT-1402 was specifically designed to spare albumin and lipids. Like the approved FcRn blockers efgartigimod, nipocalimab and rozanolixizumab it lowers circulating IgG - including pathogenic autoantibodies - but it is distinguished by two things: a low-volume subcutaneous autoinjector for at-home self-administration, and Phase 1 data showing 60-80% IgG reduction with no albumin drop and no LDL rise. It is now Immunovant's lead pipeline asset, advancing across roughly six autoimmune indications with potentially registrational Graves' disease and myasthenia gravis readouts expected in 2027. View Details: https://peptrackerpro.com/peptides/imvt-1402 \+ Compare: https://peptrackerpro.com/compare?select=imvt-1402 Track in App: https://app.peptrackerpro.com/?add=imvt-1402 ### Inclisiran High Evidence An approved, twice-yearly subcutaneous GalNAc-conjugated small interfering RNA (siRNA) from Novartis (originally discovered by Alnylam) that lowers LDL cholesterol by silencing PCSK9 (proprotein convertase subtilisin/kexin type 9), the liver protein that destroys LDL receptors. By switching off PCSK9 production inside hepatocytes, inclisiran leaves more LDL receptors on the liver surface to pull LDL cholesterol out of the blood - achieving roughly a 50% LDL reduction with an injection given only twice a year after a loading dose. Marketed as Leqvio, it was the first siRNA medicine approved for a chronic cardiovascular condition: the EU cleared it in December 2020 and the FDA in December 2021, and in July 2025 the FDA expanded the U.S. label to first-line monotherapy, dropping the requirement that it be added on top of a statin. Its Phase 3 ORION-9, ORION-10 and ORION-11 trials established the LDL benefit; a large cardiovascular outcomes program (VICTORION-2-PREVENT and others) is still running to test whether that LDL lowering prevents heart attacks and strokes. Inclisiran is the approved, real-world proof-of-concept for the GalNAc-siRNA cardiometabolic platform that newer investigational agents like zodasiran, solbinsiran, olpasiran and plozasiran build on. Cardiovascular: https://peptrackerpro.com/benefits/cardiovascular Cholesterol Management: https://peptrackerpro.com/benefits/cholesterol-management Disease Modification: https://peptrackerpro.com/benefits/disease-modification View Details: https://peptrackerpro.com/peptides/inclisiran \+ Compare: https://peptrackerpro.com/compare?select=inclisiran Track in App: https://app.peptrackerpro.com/?add=inclisiran ### Insulin Efsitora Alfa High Evidence A once-weekly basal insulin engineered as a single-chain insulin analog fused to an antibody (IgG2) Fc fragment, giving it a roughly 17-day half-life so a single subcutaneous injection covers a full week. Developed by Eli Lilly (code LY3209590, also called basal insulin Fc or BIF), efsitora is designed to replace daily long-acting insulin with a flat, ultra-stable weekly profile. In the large Phase 3 QWINT program it matched daily insulins glargine and degludec on A1C in type 2 diabetes, and in insulin-naive patients its simplified fixed-dose titration cut the number of dose adjustments dramatically while keeping hypoglycemia low. In type 1 diabetes (QWINT-5) it was non-inferior on A1C but showed a higher rate of severe hypoglycemia, a key safety caveat. As of mid-2026 efsitora is under FDA review for type 2 diabetes (a decision expected in the third quarter of 2026) and would compete directly with Novo Nordisk's once-weekly insulin icodec (Awiqli). Glycemic Control: https://peptrackerpro.com/benefits/glycemic-control Hormone Support: https://peptrackerpro.com/benefits/hormone-support View Details: https://peptrackerpro.com/peptides/insulin-efsitora-alfa \+ Compare: https://peptrackerpro.com/compare?select=insulin-efsitora-alfa Track in App: https://app.peptrackerpro.com/?add=insulin-efsitora-alfa ### Ipamorelin Medium Evidence A selective growth hormone secretagogue studied for targeted GH release with fewer side effects than other GH peptides. View Details: https://peptrackerpro.com/peptides/ipamorelin \+ Compare: https://peptrackerpro.com/compare?select=ipamorelin Track in App: https://app.peptrackerpro.com/?add=ipamorelin ### KAI-7535 Medium Evidence An oral once-daily small-molecule GLP-1 receptor agonist (Hengrui's HRS-7535, licensed to Kailera) that delivered up to 10.9% weight loss at Week 44 in a Chinese Phase 3 obesity trial and met its Phase 3 diabetes endpoint, now in a global Phase 2 dose-optimization study. View Details: https://peptrackerpro.com/peptides/kai-7535 \+ Compare: https://peptrackerpro.com/compare?select=kai-7535 Track in App: https://app.peptrackerpro.com/?add=kai-7535 ### Kisspeptin-10 Medium Evidence A neuropeptide that stimulates GnRH release, studied for fertility and reproductive hormone regulation. Fertility: https://peptrackerpro.com/benefits/fertility Hormone Support: https://peptrackerpro.com/benefits/hormone-support Sexual Health: https://peptrackerpro.com/benefits/sexual-health View Details: https://peptrackerpro.com/peptides/kisspeptin-10 \+ Compare: https://peptrackerpro.com/compare?select=kisspeptin-10 Track in App: https://app.peptrackerpro.com/?add=kisspeptin-10 ### Klotho (Alpha-Klotho) Low Evidence A naturally occurring longevity hormone (secreted alpha-klotho) being studied for cognition and brain aging; a single low-dose injection improved memory in aged monkeys, and a first-in-human Phase 1 trial in older adults is underway. Cognition: https://peptrackerpro.com/benefits/cognition Neuroprotection: https://peptrackerpro.com/benefits/neuroprotection Anti-Aging: https://peptrackerpro.com/benefits/anti-aging Longevity: https://peptrackerpro.com/benefits/longevity View Details: https://peptrackerpro.com/peptides/klotho \+ Compare: https://peptrackerpro.com/compare?select=klotho Track in App: https://app.peptrackerpro.com/?add=klotho ### KLOW Low Evidence A multi-peptide blend combining BPC-157, TB-500, GHK-Cu, and KPV for comprehensive tissue repair and anti-inflammatory support. Recovery: https://peptrackerpro.com/benefits/recovery Wound Healing: https://peptrackerpro.com/benefits/wound-healing Inflammation: https://peptrackerpro.com/benefits/inflammation Skin: https://peptrackerpro.com/benefits/skin View Details: https://peptrackerpro.com/peptides/klow \+ Compare: https://peptrackerpro.com/compare?select=klow Track in App: https://app.peptrackerpro.com/?add=klow ### KPV Medium Evidence A tripeptide derived from alpha-MSH, studied for anti-inflammatory and gut-protective properties. Inflammation: https://peptrackerpro.com/benefits/inflammation Gut Health: https://peptrackerpro.com/benefits/gut-health Skin: https://peptrackerpro.com/benefits/skin Immune Support: https://peptrackerpro.com/benefits/immune-support View Details: https://peptrackerpro.com/peptides/kpv \+ Compare: https://peptrackerpro.com/compare?select=kpv Track in App: https://app.peptrackerpro.com/?add=kpv ### Larazotide Medium Evidence A synthetic peptide tight junction regulator in clinical trials for celiac disease, designed to prevent intestinal permeability caused by gluten exposure. Gut Health: https://peptrackerpro.com/benefits/gut-health Inflammation: https://peptrackerpro.com/benefits/inflammation Immune Support: https://peptrackerpro.com/benefits/immune-support View Details: https://peptrackerpro.com/peptides/larazotide \+ Compare: https://peptrackerpro.com/compare?select=larazotide Track in App: https://app.peptrackerpro.com/?add=larazotide ### Lepodisiran Medium Evidence An investigational, long-duration injectable small interfering RNA (siRNA) from Eli Lilly that lowers lipoprotein(a) [Lp(a)] by nearly 94% by silencing the LPA gene in the liver. A single dose keeps Lp(a) suppressed for a year or more, and its Phase 3 ACCLAIM-Lp(a) trial (~12,500 patients) is the first Lp(a) outcomes trial to include people who have not yet had a cardiovascular event. View Details: https://peptrackerpro.com/peptides/lepodisiran \+ Compare: https://peptrackerpro.com/compare?select=lepodisiran Track in App: https://app.peptrackerpro.com/?add=lepodisiran ### LIPO-C Low Evidence A lipotropic injection blend containing methionine, inositol, choline, and other compounds to support fat metabolism. View Details: https://peptrackerpro.com/peptides/lipo-c \+ Compare: https://peptrackerpro.com/compare?select=lipo-c Track in App: https://app.peptrackerpro.com/?add=lipo-c ### LL-37 Medium Evidence A human antimicrobial peptide studied for innate immunity, wound healing, and biofilm disruption. Immune Support: https://peptrackerpro.com/benefits/immune-support Wound Healing: https://peptrackerpro.com/benefits/wound-healing Inflammation: https://peptrackerpro.com/benefits/inflammation Skin: https://peptrackerpro.com/benefits/skin View Details: https://peptrackerpro.com/peptides/ll-37 \+ Compare: https://peptrackerpro.com/compare?select=ll-37 Track in App: https://app.peptrackerpro.com/?add=ll-37 ### Lonapegsomatropin High Evidence Lonapegsomatropin (brand name Skytrofa, developed as TransCon hGH by Ascendis Pharma) is a long-acting, once-weekly prodrug of human growth hormone (somatropin) approved to treat growth hormone deficiency (GHD). Unlike conventional recombinant growth hormone, which must be injected every day, lonapegsomatropin uses Ascendis's TransCon ("transient conjugation") technology to slowly release fully active, unmodified growth hormone from an inert carrier over the course of a week, so patients inject only once weekly. It is built from three parts - unmodified somatropin, a methoxypolyethylene glycol (mPEG) carrier that shields the hormone and extends its time in the body, and a TransCon linker that connects them and then self-cleaves at normal body pH and temperature to release native growth hormone at a controlled, predictable rate. The FDA first approved lonapegsomatropin in August 2021 for children one year and older with GHD (the pivotal Phase 3 heiGHt trial showed it was non-inferior and numerically superior to daily somatropin for annualized height velocity in treatment-naive children), and in July 2025 the FDA expanded approval to adults with GHD based on the Phase 3 foresiGHt trial, in which once-weekly TransCon hGH significantly reduced trunk fat and increased lean body mass versus placebo. It is administered subcutaneously with the SKYTROFA Auto-Injector using a single-dose, dual-chamber prefilled cartridge. Lonapegsomatropin is a regulated prescription medicine, not a supplement or research chemical, and shares the class safety profile of growth hormone therapy. endocrine: https://peptrackerpro.com/benefits/endocrine growth: https://peptrackerpro.com/benefits/growth Body Composition: https://peptrackerpro.com/benefits/body-composition metabolic: https://peptrackerpro.com/benefits/metabolic View Details: https://peptrackerpro.com/peptides/lonapegsomatropin \+ Compare: https://peptrackerpro.com/compare?select=lonapegsomatropin Track in App: https://app.peptrackerpro.com/?add=lonapegsomatropin ### Lutetium Lu 177 Vipivotide Tetraxetan (Pluvicto) High Evidence An FDA-approved PSMA-targeted radioligand therapy (brand name Pluvicto) for advanced prostate cancer. It pairs a small PSMA-binding ligand with the radioactive isotope lutetium-177 to deliver radiation directly to cancer cells. In 2026 it gained major traction after the Phase 3 PSMAddition trial showed benefit in earlier, hormone-sensitive disease. Oncology: https://peptrackerpro.com/benefits/oncology View Details: https://peptrackerpro.com/peptides/pluvicto \+ Compare: https://peptrackerpro.com/compare?select=pluvicto Track in App: https://app.peptrackerpro.com/?add=pluvicto ### Maridebart Cafraglutide (MariTide) Medium Evidence Amgen's once-monthly injectable GIP receptor antagonist and GLP-1 receptor agonist, showing up to 20% weight loss in phase 2 trials with a unique mechanism that blocks GIP while activating GLP-1. Weight Management: https://peptrackerpro.com/benefits/weight-management Metabolism: https://peptrackerpro.com/benefits/metabolism Appetite Regulation: https://peptrackerpro.com/benefits/appetite-regulation Fat Loss: https://peptrackerpro.com/benefits/fat-loss View Details: https://peptrackerpro.com/peptides/maridebart-cafraglutide \+ Compare: https://peptrackerpro.com/compare?select=maridebart-cafraglutide Track in App: https://app.peptrackerpro.com/?add=maridebart-cafraglutide ### MariTide High Evidence A bispecific GIPR antagonist and GLP-1 receptor agonist antibody-peptide conjugate developed by Amgen for obesity and type 2 diabetes. View Details: https://peptrackerpro.com/peptides/maritide \+ Compare: https://peptrackerpro.com/compare?select=maritide Track in App: https://app.peptrackerpro.com/?add=maritide ### Mazdutide High Evidence The first dual GCG/GLP-1 receptor agonist approved in China for obesity and T2D, with Phase 3 showing up to 20.1% weight loss at the 9 mg dose and superiority over semaglutide. View Details: https://peptrackerpro.com/peptides/mazdutide \+ Compare: https://peptrackerpro.com/compare?select=mazdutide Track in App: https://app.peptrackerpro.com/?add=mazdutide ### MBX 4291 Low Evidence A GLP-1/GIP co-agonist prodrug engineered for once-monthly dosing using MBX Biosciences' PEP platform. Phase 1 blinded data showed 7% mean weight loss at 8 weeks with minimal GI side effects. View Details: https://peptrackerpro.com/peptides/mbx-4291 \+ Compare: https://peptrackerpro.com/compare?select=mbx-4291 Track in App: https://app.peptrackerpro.com/?add=mbx-4291 ### MBX 5765 Low Evidence A novel quadruple agonist prodrug combining GLP-1, GIP, glucagon, and DACRA (dual amylin and calcitonin receptor agonist) activity in a single molecule, designed for once-monthly dosing and superior efficacy. View Details: https://peptrackerpro.com/peptides/mbx-5765 \+ Compare: https://peptrackerpro.com/compare?select=mbx-5765 Track in App: https://app.peptrackerpro.com/?add=mbx-5765 ### MET-097i Medium Evidence An ultra-long-acting GLP-1 receptor agonist designed for both once-weekly and once-monthly subcutaneous dosing, delivering double-digit weight loss with class-leading gastrointestinal tolerability in mid-stage trials. View Details: https://peptrackerpro.com/peptides/met-097i \+ Compare: https://peptrackerpro.com/compare?select=met-097i Track in App: https://app.peptrackerpro.com/?add=met-097i ### MET-233i Medium Evidence MET-233i is a first-in-class, once-monthly ultra-long-acting amylin analog for obesity, originally developed by Metsera and now a Pfizer asset. In its Phase 1 trial it produced up to 8.4% placebo-subtracted weight loss after five weekly doses and showed a roughly 19-day half-life - the most durable of any reported amylin analog - supporting once-monthly subcutaneous dosing. It is engineered to be combined with Metsera's monthly GLP-1 agonist MET-097i in a single once-monthly injection. View Details: https://peptrackerpro.com/peptides/met-233i \+ Compare: https://peptrackerpro.com/compare?select=met-233i Track in App: https://app.peptrackerpro.com/?add=met-233i ### Motixafortide (Aphexda) High Evidence An FDA-approved synthetic cyclic peptide and CXCR4 antagonist (brand name Aphexda; research name BL-8040) used together with G-CSF to mobilize blood-forming stem cells for autologous transplant in multiple myeloma. In 2026 it is being actively studied as part of combination immunotherapy for pancreatic cancer. Hematology: https://peptrackerpro.com/benefits/hematology Oncology: https://peptrackerpro.com/benefits/oncology Immune Modulation: https://peptrackerpro.com/benefits/immune-modulation View Details: https://peptrackerpro.com/peptides/motixafortide \+ Compare: https://peptrackerpro.com/compare?select=motixafortide Track in App: https://app.peptrackerpro.com/?add=motixafortide ### MOTS-c Low Evidence A mitochondrial-derived peptide studied for metabolic regulation, exercise mimetic effects, and longevity. Metabolism (https://peptrackerpro.com/benefits/metabolism)Fat Loss (https://peptrackerpro.com/benefits/fat-loss)Longevity (https://peptrackerpro.com/benefits/longevity)Muscle Growth (https://peptrackerpro.com/benefits/muscle-growth)+2 more View Details: https://peptrackerpro.com/peptides/mots-c \+ Compare: https://peptrackerpro.com/compare?select=mots-c Track in App: https://app.peptrackerpro.com/?add=mots-c ### MT-1 (Melanotan I) High Evidence A melanocortin receptor agonist FDA-approved (in Europe) for preventing phototoxicity in erythropoietic protoporphyria. Pigmentation: https://peptrackerpro.com/benefits/pigmentation Skin: https://peptrackerpro.com/benefits/skin View Details: https://peptrackerpro.com/peptides/mt-1 \+ Compare: https://peptrackerpro.com/compare?select=mt-1 Track in App: https://app.peptrackerpro.com/?add=mt-1 ### MT-2 (Melanotan II) Medium Evidence A melanocortin receptor agonist studied for tanning, sexual function, and appetite suppression. Pigmentation: https://peptrackerpro.com/benefits/pigmentation Sexual Health: https://peptrackerpro.com/benefits/sexual-health Fat Loss: https://peptrackerpro.com/benefits/fat-loss View Details: https://peptrackerpro.com/peptides/mt-2 \+ Compare: https://peptrackerpro.com/compare?select=mt-2 Track in App: https://app.peptrackerpro.com/?add=mt-2 ### Muvalaplin Medium Evidence The first oral, small-molecule inhibitor of lipoprotein(a) [Lp(a)] formation, from Eli Lilly. Instead of silencing a gene, muvalaplin is a once-daily pill that physically blocks apolipoprotein(a) from binding apolipoprotein B — the first step in building an Lp(a) particle. In its Phase 2 KRAKEN trial (published in JAMA, 2024) it cut Lp(a) by up to ~86% (placebo-adjusted) and, as of 2026, is the only Lp(a)-lowering drug that is both oral and already enrolling a large Phase 3 cardiovascular outcomes trial (MOVE-Lp(a)). View Details: https://peptrackerpro.com/peptides/muvalaplin \+ Compare: https://peptrackerpro.com/compare?select=muvalaplin Track in App: https://app.peptrackerpro.com/?add=muvalaplin ### NA-931 (Bioglutide) Medium Evidence The first oral quadruple receptor agonist targeting IGF-1, GLP-1, GIP, and glucagon receptors for obesity treatment with muscle preservation. Weight Management (https://peptrackerpro.com/benefits/weight-management)Fat Loss (https://peptrackerpro.com/benefits/fat-loss)Muscle Preservation (https://peptrackerpro.com/benefits/muscle-preservation)Metabolism (https://peptrackerpro.com/benefits/metabolism)+1 more View Details: https://peptrackerpro.com/peptides/na-931 \+ Compare: https://peptrackerpro.com/compare?select=na-931 Track in App: https://app.peptrackerpro.com/?add=na-931 ### NAD+ Medium Evidence A coenzyme essential for cellular energy production, studied for anti-aging and metabolic support. Energy (https://peptrackerpro.com/benefits/energy)Longevity (https://peptrackerpro.com/benefits/longevity)Anti-Aging (https://peptrackerpro.com/benefits/anti-aging)Metabolism (https://peptrackerpro.com/benefits/metabolism)+1 more View Details: https://peptrackerpro.com/peptides/nad \+ Compare: https://peptrackerpro.com/compare?select=nad Track in App: https://app.peptrackerpro.com/?add=nad ### Navepegritide High Evidence A C-type natriuretic peptide (CNP) analog FDA-approved in February 2026 for increasing linear growth in children with achondroplasia — the first once-weekly CNP therapy. Joint Health: https://peptrackerpro.com/benefits/joint-health Hormone Support: https://peptrackerpro.com/benefits/hormone-support View Details: https://peptrackerpro.com/peptides/navepegritide \+ Compare: https://peptrackerpro.com/compare?select=navepegritide Track in App: https://app.peptrackerpro.com/?add=navepegritide ### Nipocalimab High Evidence Nipocalimab (brand name Imaavy, development code M281) is a fully human, aglycosylated, 'effectorless' IgG1 monoclonal antibody that blocks the neonatal Fc receptor (FcRn), developed by Johnson & Johnson (Janssen). Like efgartigimod it lowers circulating immunoglobulin G (IgG) - including the pathogenic autoantibodies that drive many autoimmune diseases - by occupying FcRn and preventing it from recycling IgG back into the blood, so unrescued IgG is routed to the lysosome and degraded, typically cutting total IgG by roughly 65-75% while sparing IgM, IgA, complement, and albumin. Unlike efgartigimod's engineered Fc fragment, nipocalimab is a full-length monoclonal antibody engineered to be aglycosylated and effectorless (it does not trigger ADCC or complement-dependent cytotoxicity), and it is dosed as a maintenance intravenous infusion for continuous IgG suppression rather than in short cycles. The FDA approved Imaavy on April 30, 2025 for generalized myasthenia gravis (gMG) in anti-AChR-antibody-positive and anti-MuSK-antibody-positive patients aged 12 and older - making it the first FcRn blocker approved for adolescents and the first to explicitly cover MuSK-positive disease - on the strength of the Phase 3 Vivacity-MG3 trial. It has since generated positive data across a striking breadth of IgG-mediated conditions: Sjogren's disease (Phase 2 DAHLIAS), rheumatoid arthritis, warm autoimmune hemolytic anemia (wAIHA), and - uniquely among FcRn blockers - maternal-fetal alloimmune disease, where it is being developed to treat hemolytic disease of the fetus and newborn (HDFN) by crossing the placenta to protect the fetus. In April 2026 the FDA granted Priority Review to nipocalimab for wAIHA, positioning it as a potential first approved therapy for that condition. View Details: https://peptrackerpro.com/peptides/nipocalimab \+ Compare: https://peptrackerpro.com/compare?select=nipocalimab Track in App: https://app.peptrackerpro.com/?add=nipocalimab ### Nucresiran Medium Evidence An investigational next-generation RNA interference (RNAi) therapeutic from Alnylam Pharmaceuticals designed to silence the transthyretin (TTR) gene and treat transthyretin amyloidosis (ATTR) - the same disease targeted by Alnylam's approved drugs patisiran and vutrisiran (Amvuttra) and by Ionis/AstraZeneca's eplontersen (Wainua/Wainzua). Nucresiran (formerly ALN-TTRsc04) is a subcutaneous GalNAc-conjugated small interfering RNA (siRNA) built on Alnylam's newer IKARIA platform, engineered for deeper, more durable knockdown of both mutant and wild-type TTR with the potential for once- or twice-yearly dosing - a substantial step beyond the current quarterly (vutrisiran) or monthly (eplontersen) schedules. In an interim Phase 1 single-ascending-dose study in 48 healthy volunteers (presented at AHA 2024), a single dose of 300 mg or higher rapidly lowered serum TTR by more than 90% by Day 15 and by more than 96% at peak (Day 29), with more than 70% reduction still present at one year after a single 300 mg dose and low patient-to-patient variability; all doses were well tolerated with no injection-site reactions and no liver safety signals. Alnylam has moved nucresiran into a Phase 3 TRITON program: TRITON-PN (NCT07223203) in hereditary ATTR with polyneuropathy, an open-label study using vutrisiran as an active comparator, and TRITON-CM (NCT07052903), a large event-driven cardiovascular outcomes trial in ATTR cardiomyopathy dosing nucresiran 300 mg subcutaneously once every six months. Nucresiran is investigational and not approved by the FDA, EMA or any regulator; it is studied only in clinical trials and is not a supplement or research chemical. Cardiovascular: https://peptrackerpro.com/benefits/cardiovascular Neuroprotection: https://peptrackerpro.com/benefits/neuroprotection Disease Modification: https://peptrackerpro.com/benefits/disease-modification Rare Disease Treatment: https://peptrackerpro.com/benefits/rare-disease-treatment View Details: https://peptrackerpro.com/peptides/nucresiran \+ Compare: https://peptrackerpro.com/compare?select=nucresiran Track in App: https://app.peptrackerpro.com/?add=nucresiran ### Obicetrapib Medium Evidence An investigational once-daily oral, highly selective CETP (cholesteryl ester transfer protein) inhibitor from NewAmsterdam Pharma (European partner Menarini) that lowers LDL cholesterol and lipoprotein(a) [Lp(a)] in a single pill. Unlike the failed first-generation CETP inhibitors, obicetrapib is valued for LDL and Lp(a) lowering rather than HDL raising. In Phase 3 it cut LDL-C by about a third as monotherapy (BROADWAY) and by roughly half combined with ezetimibe (TANDEM), and reduced Lp(a) by ~33% - published in NEJM and The Lancet (2025). It received a positive EMA CHMP opinion in July 2026 (as Ubeslo and Evlarco), with the PREVAIL cardiovascular outcomes trial due to report in 2026. View Details: https://peptrackerpro.com/peptides/obicetrapib \+ Compare: https://peptrackerpro.com/compare?select=obicetrapib Track in App: https://app.peptrackerpro.com/?add=obicetrapib ### Olezarsen High Evidence An FDA-approved subcutaneous antisense oligonucleotide (ASO) from Ionis Pharmaceuticals, branded Tryngolza, that lowers triglycerides by silencing the messenger RNA for apolipoprotein C-III (apoC-III). Self-injected once a month, it was the first-ever therapy approved for familial chylomicronemia syndrome (FCS) on December 19, 2024, and on June 24, 2026 it became the first and only treatment approved to reduce both triglycerides and the risk of acute pancreatitis in the far larger severe hypertriglyceridemia (sHTG) population. View Details: https://peptrackerpro.com/peptides/olezarsen \+ Compare: https://peptrackerpro.com/compare?select=olezarsen Track in App: https://app.peptrackerpro.com/?add=olezarsen ### Olpasiran Medium Evidence An investigational, once-every-12-weeks injectable small interfering RNA (siRNA) from Amgen that lowers lipoprotein(a) [Lp(a)] by up to ~97% by silencing the LPA gene in the liver. Its Phase 3 OCEAN(a)-Outcomes cardiovascular outcomes trial (~7,000 patients) is one of the pivotal readouts — due December 2026 — that will help decide whether lowering Lp(a) prevents heart attacks and strokes. View Details: https://peptrackerpro.com/peptides/olpasiran \+ Compare: https://peptrackerpro.com/compare?select=olpasiran Track in App: https://app.peptrackerpro.com/?add=olpasiran ### Orforglipron High Evidence The first oral non-peptide GLP-1 receptor agonist, FDA-approved in April 2026 for chronic weight management with no food or water restrictions. View Details: https://peptrackerpro.com/peptides/orforglipron \+ Compare: https://peptrackerpro.com/compare?select=orforglipron Track in App: https://app.peptrackerpro.com/?add=orforglipron ### Oxytocin High Evidence A neuropeptide involved in social bonding, mood regulation, and reproductive functions. Mood: https://peptrackerpro.com/benefits/mood Anxiety Relief: https://peptrackerpro.com/benefits/anxiety-relief Hormone Support: https://peptrackerpro.com/benefits/hormone-support View Details: https://peptrackerpro.com/peptides/oxytocin \+ Compare: https://peptrackerpro.com/compare?select=oxytocin Track in App: https://app.peptrackerpro.com/?add=oxytocin ### P21 Medium Evidence An 11-amino-acid CNTF-derived peptide studied for its ability to upregulate BDNF expression and promote neurogenesis in cognitive decline models. View Details: https://peptrackerpro.com/peptides/p21 \+ Compare: https://peptrackerpro.com/compare?select=p21 Track in App: https://app.peptrackerpro.com/?add=p21 ### Palopegteriparatide High Evidence Palopegteriparatide (Yorvipath, developed as TransCon PTH) is Ascendis Pharma's once-daily prodrug of parathyroid hormone (1-34). An inert methoxy-PEG carrier is attached to PTH(1-34) through a TransCon linker that auto-cleaves at physiologic pH and temperature, releasing unmodified native-sequence PTH slowly enough to hold hormone levels inside the physiologic range for a full 24 hours. It is the first therapy approved as a true hormone replacement for chronic hypoparathyroidism rather than as an add-on to calcium and active vitamin D: in the Phase 3 PaTHway trial 78.7% of treated adults met a composite endpoint of normal serum calcium plus independence from conventional therapy at week 26, versus 4.8% on placebo. The FDA approved Yorvipath on August 9, 2024. Rare Disease Treatment (https://peptrackerpro.com/benefits/rare-disease-treatment)Hormone Support (https://peptrackerpro.com/benefits/hormone-support)Bone Growth (https://peptrackerpro.com/benefits/bone-growth)Disease Modification (https://peptrackerpro.com/benefits/disease-modification)+1 more View Details: https://peptrackerpro.com/peptides/palopegteriparatide \+ Compare: https://peptrackerpro.com/compare?select=palopegteriparatide Track in App: https://app.peptrackerpro.com/?add=palopegteriparatide ### PEG-MGF Low Evidence A PEGylated splice variant of IGF-1 studied for muscle repair and satellite cell activation, with an extended half-life compared to native MGF. Muscle Growth: https://peptrackerpro.com/benefits/muscle-growth Recovery: https://peptrackerpro.com/benefits/recovery Wound Healing: https://peptrackerpro.com/benefits/wound-healing View Details: https://peptrackerpro.com/peptides/peg-mgf \+ Compare: https://peptrackerpro.com/compare?select=peg-mgf Track in App: https://app.peptrackerpro.com/?add=peg-mgf ### Pegcetacoplan High Evidence A PEGylated cyclic-peptide inhibitor of complement component 3 (C3) built from two compstatin (Cp05) peptide domains bridged by a 40-kDa PEG chain; marketed as Empaveli/Aspaveli (subcutaneous, for paroxysmal nocturnal hemoglobinuria and, since July 2025, C3 glomerulopathy and primary IC-MPGN) and Syfovre (intravitreal, for geographic atrophy in age-related macular degeneration). It is one of the few complement-targeting therapeutic peptides to reach the market. Immune Support: https://peptrackerpro.com/benefits/immune-support Inflammation: https://peptrackerpro.com/benefits/inflammation View Details: https://peptrackerpro.com/peptides/pegcetacoplan \+ Compare: https://peptrackerpro.com/compare?select=pegcetacoplan Track in App: https://app.peptrackerpro.com/?add=pegcetacoplan ### Pegozafermin Medium Evidence Pegozafermin (development code BIO89-100) is an investigational, long-acting analog of fibroblast growth factor 21 (FGF21) being developed for metabolic dysfunction-associated steatohepatitis (MASH, formerly NASH) and for severe hypertriglyceridemia (SHTG). Originally developed by 89bio and acquired by Roche in a deal announced in September 2025 (about $2.4 billion upfront and up to roughly $3.5 billion including a contingent value right), it uses site-specific glycoPEGylation to extend the very short half-life of native FGF21 to roughly 55-100 hours, enabling once-weekly or once-every-two-weeks subcutaneous dosing. FGF21 is a metabolic hormone that acts on liver, fat, and other tissues to improve insulin sensitivity, lower triglycerides, and exert direct anti-fibrotic and anti-inflammatory effects. In the Phase 2b ENLIVEN trial in biopsy-confirmed F2-F3 MASH, the 44 mg every-two-weeks dose produced at least a one-stage fibrosis improvement without worsening of MASH in about 27% of patients versus 7% on placebo, and MASH resolution without worsening of fibrosis in about 26% versus 2% on placebo, with benefits sustained through week 48. Pegozafermin holds FDA Breakthrough Therapy designation and EMA PRIME status for MASH and has advanced into the Phase 3 ENLIGHTEN program (ENLIGHTEN-Fibrosis in non-cirrhotic F2-F3 MASH and ENLIGHTEN-Cirrhosis in compensated F4 cirrhosis), plus the Phase 3 ENTRUST trial in SHTG. View Details: https://peptrackerpro.com/peptides/pegozafermin \+ Compare: https://peptrackerpro.com/compare?select=pegozafermin Track in App: https://app.peptrackerpro.com/?add=pegozafermin ### Pelacarsen Medium Evidence A first-in-class, once-monthly injectable antisense oligonucleotide (ASO) from Ionis and Novartis that lowers lipoprotein(a) [Lp(a)] by shutting down apolipoprotein(a) production in the liver. Its pivotal Lp(a)HORIZON trial (8,323 patients) is the first-ever cardiovascular outcomes trial for any Lp(a)-lowering drug, with a landmark topline readout due in 2026. View Details: https://peptrackerpro.com/peptides/pelacarsen \+ Compare: https://peptrackerpro.com/compare?select=pelacarsen Track in App: https://app.peptrackerpro.com/?add=pelacarsen ### Pemvidutide Medium Evidence A GLP-1/glucagon dual receptor agonist with FDA Breakthrough Therapy Designation for MASH, showing strong weight loss and liver benefits in Phase 2 trials. Weight Management: https://peptrackerpro.com/benefits/weight-management Fat Loss: https://peptrackerpro.com/benefits/fat-loss Liver Health: https://peptrackerpro.com/benefits/liver-health Metabolism: https://peptrackerpro.com/benefits/metabolism View Details: https://peptrackerpro.com/peptides/pemvidutide \+ Compare: https://peptrackerpro.com/compare?select=pemvidutide Track in App: https://app.peptrackerpro.com/?add=pemvidutide ### Pentosan Polysulfate High Evidence A semi-synthetic polysaccharide FDA-approved for interstitial cystitis and studied for joint health applications. Joint Health: https://peptrackerpro.com/benefits/joint-health Inflammation: https://peptrackerpro.com/benefits/inflammation Pain Relief: https://peptrackerpro.com/benefits/pain-relief View Details: https://peptrackerpro.com/peptides/pentosan-polysulfate \+ Compare: https://peptrackerpro.com/compare?select=pentosan-polysulfate Track in App: https://app.peptrackerpro.com/?add=pentosan-polysulfate ### Pep19 Low Evidence An orally dosed synthetic intracellular peptide that acts on the endocannabinoid system; an early human trial showed reduced visceral fat and improved sleep without lean-mass loss. Fat Loss: https://peptrackerpro.com/benefits/fat-loss Metabolism: https://peptrackerpro.com/benefits/metabolism Sleep: https://peptrackerpro.com/benefits/sleep View Details: https://peptrackerpro.com/peptides/pep19 \+ Compare: https://peptrackerpro.com/compare?select=pep19 Track in App: https://app.peptrackerpro.com/?add=pep19 ### Petrelintide Medium Evidence A long-acting amylin analog in late-stage clinical development for chronic weight management, designed to deliver double-digit weight loss with a tolerability profile comparable to placebo. View Details: https://peptrackerpro.com/peptides/petrelintide \+ Compare: https://peptrackerpro.com/compare?select=petrelintide Track in App: https://app.peptrackerpro.com/?add=petrelintide ### PF-08653944 Medium Evidence An ultra-long-acting injectable GLP-1 receptor agonist enabling monthly dosing, with 12.3% placebo-adjusted weight loss in Phase 2b and 10 Phase 3 trials planned. View Details: https://peptrackerpro.com/peptides/pf-08653944 \+ Compare: https://peptrackerpro.com/compare?select=pf-08653944 Track in App: https://app.peptrackerpro.com/?add=pf-08653944 ### Pinealon Low Evidence A short bioregulatory peptide studied for neuroprotective effects and cognitive support in aging. View Details: https://peptrackerpro.com/peptides/pinealon \+ Compare: https://peptrackerpro.com/compare?select=pinealon Track in App: https://app.peptrackerpro.com/?add=pinealon ### Plozasiran High Evidence An approved subcutaneous RNA interference (RNAi) therapy from Arrowhead Pharmaceuticals, branded Redemplo, that silences the gene for apolipoprotein C-III (apoC-III) to lower triglycerides. Given once every three months, it cut triglycerides by roughly 80% in familial chylomicronemia syndrome (FCS) and sharply reduced acute pancreatitis events. The FDA approved it on November 18, 2025 for FCS, and Phase 3 SHASTA-3 and SHASTA-4 (reported July 2026) extended those results to the far larger severe hypertriglyceridemia population. View Details: https://peptrackerpro.com/peptides/plozasiran \+ Compare: https://peptrackerpro.com/compare?select=plozasiran Track in App: https://app.peptrackerpro.com/?add=plozasiran ### Povetacicept High Evidence Povetacicept (development code ALPN-303) is an investigational, once-monthly, subcutaneously injected recombinant fusion protein that simultaneously blocks two B-cell survival signals - BAFF (B-cell activating factor) and APRIL (a proliferation-inducing ligand). It is built from an engineered ('variant') form of the natural TACI receptor's extracellular domain fused to an antibody (IgG) Fc region, so it acts as a high-affinity decoy that soaks up both BAFF and APRIL before they can reach their receptors on B cells and plasma cells. Because BAFF and APRIL drive the maturation and antibody production of the immune cells behind many autoantibody- and immune-complex-mediated diseases, povetacicept is being developed for B-cell-driven autoimmune conditions - most prominently IgA nephropathy (IgAN), where APRIL fuels the production of the galactose-deficient IgA1 that damages the kidney. Originated by Alpine Immune Sciences (acquired by Vertex Pharmaceuticals in 2024), povetacicept has received FDA Breakthrough Therapy Designation for IgAN; in March 2026 the Phase 3 RAINIER trial reported a positive prespecified Week 36 interim analysis (a ~52% reduction in urine protein-to-creatinine ratio from baseline and a ~50% reduction versus placebo), and in June 2026 the FDA accepted a Biologics License Application for accelerated approval with a target action date of November 30, 2026. Povetacicept is an experimental biologic given only in clinical trials; it is not a supplement, nootropic, or research chemical. View Details: https://peptrackerpro.com/peptides/povetacicept \+ Compare: https://peptrackerpro.com/compare?select=povetacicept Track in App: https://app.peptrackerpro.com/?add=povetacicept ### PT-141 High Evidence A melanocortin receptor agonist FDA-approved for hypoactive sexual desire disorder in premenopausal women. Sexual Health: https://peptrackerpro.com/benefits/sexual-health View Details: https://peptrackerpro.com/peptides/pt-141 \+ Compare: https://peptrackerpro.com/compare?select=pt-141 Track in App: https://app.peptrackerpro.com/?add=pt-141 ### PTP-r Low Evidence A next-generation mitochondria-targeting peptide that induces selective adipocyte apoptosis and mitochondrial uncoupling for weight loss without systemic toxicity. Weight Management: https://peptrackerpro.com/benefits/weight-management Fat Loss: https://peptrackerpro.com/benefits/fat-loss Metabolism: https://peptrackerpro.com/benefits/metabolism View Details: https://peptrackerpro.com/peptides/ptp-r \+ Compare: https://peptrackerpro.com/compare?select=ptp-r Track in App: https://app.peptrackerpro.com/?add=ptp-r ### Remternetug Medium Evidence Remternetug (development code LY3372993) is an investigational IgG1 monoclonal antibody from Eli Lilly that binds a pyroglutamate-modified form of amyloid-beta (N3pG-Aβ) found almost exclusively in the aggregated plaques of Alzheimer's disease. It is the follow-on to donanemab (Kisunla), Lilly's FDA-approved anti-amyloid antibody that hits the same target, and is designed to clear existing brain amyloid rapidly and, distinctively, to be delivered by a short subcutaneous injection that patients or care partners can give at home rather than only by intravenous infusion in a clinic. In an early-phase study three-quarters of treated participants reached the amyloid-clearance threshold within about six months, and remternetug is now in Phase 3 across symptomatic early Alzheimer's (TRAILRUNNER-ALZ 1), a large prevention program (TRAILRUNNER-ALZ 3), and inherited-Alzheimer prevention through the DIAN-TU network. It is not approved by the FDA or any regulator for any use. Cognition: https://peptrackerpro.com/benefits/cognition Neuroprotection: https://peptrackerpro.com/benefits/neuroprotection Disease Modification: https://peptrackerpro.com/benefits/disease-modification View Details: https://peptrackerpro.com/peptides/remternetug \+ Compare: https://peptrackerpro.com/compare?select=remternetug Track in App: https://app.peptrackerpro.com/?add=remternetug ### Retatrutide High Evidence An investigational triple agonist (GIP/GLP-1/glucagon) studied for obesity and metabolic disease. View Details: https://peptrackerpro.com/peptides/retatrutide \+ Compare: https://peptrackerpro.com/compare?select=retatrutide Track in App: https://app.peptrackerpro.com/?add=retatrutide ### Ribupatide Medium Evidence A once-weekly injectable GLP-1/GIP dual receptor agonist in Phase 3 trials for obesity, with an oral formulation in development and backed by a record-setting $625M biotech IPO. View Details: https://peptrackerpro.com/peptides/ribupatide \+ Compare: https://peptrackerpro.com/compare?select=ribupatide Track in App: https://app.peptrackerpro.com/?add=ribupatide ### Rocatinlimab High Evidence Rocatinlimab (AMG 451 / KHK4083) is an investigational anti-OX40 monoclonal antibody developed by Kyowa Kirin and Amgen for moderate-to-severe atopic dermatitis (eczema). Unlike amlitelimab, which blocks the OX40 ligand (OX40L) on antigen-presenting cells without depleting cells, rocatinlimab binds the OX40 receptor directly on activated pathogenic T cells and reduces (depletes) them - a 'T-cell rebalancing' approach meant to reset the immune drivers of chronic inflammation rather than continuously neutralize a single cytokine. In the large Phase 3 ROCKET program the drug met its co-primary endpoints: in ROCKET-IGNITE (NCT05398445; 769 adults, added to topical therapy) week-24 EASI-75 reached about 42% (higher dose) and 36% (lower dose) versus roughly 13% on placebo, and vIGA-AD 0/1 reached about 24% and 19%; in the ROCKET-HORIZON monotherapy study (NCT05651711) EASI-75 was about 33% versus 14% on placebo, though the drug showed no superiority over dupilumab. The pooled Phase 3 results were published in The Lancet in 2025. Despite hitting its endpoints, the program then unraveled on two fronts: in January 2026 Amgen ended the collaboration on strategic-portfolio grounds and returned global rights to Kyowa Kirin, and on March 3, 2026 Kyowa Kirin discontinued ALL rocatinlimab clinical trials - across atopic dermatitis, prurigo nodularis and uncontrolled asthma - after a safety review identified cases of Kaposi's sarcoma (one newly confirmed and one suspected, in addition to a previously confirmed case) that suggested a possible mechanistic link to OX40-pathway modulation. Rocatinlimab is investigational, was never approved by any regulator, and its clinical development has been halted. View Details: https://peptrackerpro.com/peptides/rocatinlimab \+ Compare: https://peptrackerpro.com/compare?select=rocatinlimab Track in App: https://app.peptrackerpro.com/?add=rocatinlimab ### Rozanolixizumab High Evidence Rozanolixizumab (brand name Rystiggo, development code UCB7665) is a humanized IgG4 monoclonal antibody that blocks the neonatal Fc receptor (FcRn), developed by UCB. Like efgartigimod and nipocalimab it lowers circulating immunoglobulin G (IgG) - including the pathogenic autoantibodies that drive many autoimmune diseases - by binding FcRn and preventing it from recycling IgG back into the blood, so unrescued IgG is routed to the lysosome and degraded, typically cutting total IgG by roughly 70-80% while sparing IgM, IgA, complement, and albumin. Unlike efgartigimod's engineered Fc fragment, rozanolixizumab is a full-length humanized antibody, and unlike nipocalimab's intravenous infusion it is given as a rapid subcutaneous infusion (including via an on-body delivery device), typically in weekly cycles that are repeated based on clinical response rather than continuously. The FDA approved Rystiggo on June 27, 2023 for generalized myasthenia gravis (gMG) in adults who are anti-acetylcholine-receptor (AChR) antibody-positive or anti-muscle-specific-tyrosine-kinase (MuSK) antibody-positive - making it the first therapy ever approved to treat both of those gMG subtypes - on the strength of the Phase 3 MycarinG trial. It has since been studied across other IgG-mediated diseases, including chronic inflammatory demyelinating polyneuropathy (CIDP), where it did not show meaningful benefit and was not advanced to Phase 3, and myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD), primary immune thrombocytopenia (ITP), and other autoantibody conditions where development continues. The European Medicines Agency approved rozanolixizumab in January 2024 and the UK MHRA in March 2024. View Details: https://peptrackerpro.com/peptides/rozanolixizumab \+ Compare: https://peptrackerpro.com/compare?select=rozanolixizumab Track in App: https://app.peptrackerpro.com/?add=rozanolixizumab ### Rusfertide High Evidence A first-in-class synthetic hepcidin-mimetic (mini-hepcidin) peptide given as a weekly subcutaneous injection to control red-blood-cell overproduction in polycythemia vera (PV). By mimicking the iron-regulating hormone hepcidin, rusfertide binds the iron exporter ferroportin and restricts iron availability, reducing the need for therapeutic phlebotomy. Developed by Protagonist Therapeutics and partnered with Takeda, it met its primary endpoint in the Phase 3 VERIFY trial and, in March 2026, received FDA acceptance of its New Drug Application with Priority Review, with a decision expected in the third quarter of 2026. Hematology: https://peptrackerpro.com/benefits/hematology View Details: https://peptrackerpro.com/peptides/rusfertide \+ Compare: https://peptrackerpro.com/compare?select=rusfertide Track in App: https://app.peptrackerpro.com/?add=rusfertide ### Sebetralstat High Evidence Sebetralstat (brand name Ekterly) is a first-in-class, orally administered small-molecule inhibitor of plasma kallikrein and the first and only oral on-demand treatment approved for acute attacks of hereditary angioedema (HAE). HAE is a rare, sometimes life-threatening genetic disease in which unchecked activation of the plasma contact system floods the body with bradykinin, causing sudden, recurrent swelling of the skin, gut and airway. Plasma kallikrein is the enzyme that liberates bradykinin, so sebetralstat stops an attack by blocking kallikrein the moment symptoms begin - delivered as a tablet that can be taken at home rather than as an injection or infusion. The approved dose is 600 mg (two 300 mg tablets) at the earliest recognition of an attack, with a second 600 mg dose allowed at least 3 hours later if the response is inadequate or symptoms recur, up to a maximum of 1200 mg in 24 hours. Approval rests on the pivotal Phase 3 KONFIDENT trial (NCT05259917) - the largest HAE trial ever conducted, with 136 patients at 66 sites across 20 countries - a randomized, double-blind, placebo-controlled, event-driven crossover study in which sebetralstat cut the median time to the beginning of symptom relief to 1.61 hours (300 mg) and 1.79 hours (600 mg) versus 6.72 hours for placebo (p<0.0001 and p=0.0013), and also shortened the time to reduced attack severity and to complete resolution; results were published in the New England Journal of Medicine in 2024. The FDA approved Ekterly on July 7, 2025 for patients aged 12 and older, followed by European Commission and Swissmedic approvals on September 19, 2025 and UK MHRA approval. In 2026 the program widened further: an international pediatric HAE guideline named sebetralstat a first-line on-demand option for adolescents aged 12 and older, and in March 2026 KalVista reported positive interim Phase 3 results from the KONFIDENT-KID study in children aged 2 to 11 using an orally disintegrating tablet, with a US filing planned for late 2026. Developed by KalVista Pharmaceuticals, sebetralstat is a rescue (on-demand) therapy that complements the prophylactic HAE drugs garadacimab, donidalorsen, lanadelumab and berotralstat rather than replacing them. immunology: https://peptrackerpro.com/benefits/immunology rare-disease: https://peptrackerpro.com/benefits/rare-disease hereditary-angioedema: https://peptrackerpro.com/benefits/hereditary-angioedema acute-treatment: https://peptrackerpro.com/benefits/acute-treatment View Details: https://peptrackerpro.com/peptides/sebetralstat \+ Compare: https://peptrackerpro.com/compare?select=sebetralstat Track in App: https://app.peptrackerpro.com/?add=sebetralstat ### Selank Medium Evidence A synthetic peptide analog of tuftsin studied for anxiolytic and nootropic properties. Anxiety Relief (https://peptrackerpro.com/benefits/anxiety-relief)Mood (https://peptrackerpro.com/benefits/mood)Cognition (https://peptrackerpro.com/benefits/cognition)Neuroprotection (https://peptrackerpro.com/benefits/neuroprotection)+1 more View Details: https://peptrackerpro.com/peptides/selank \+ Compare: https://peptrackerpro.com/compare?select=selank Track in App: https://app.peptrackerpro.com/?add=selank ### Semaglutide High Evidence A GLP-1 receptor agonist FDA-approved for type 2 diabetes and chronic weight management. Weight Management (https://peptrackerpro.com/benefits/weight-management)Appetite Regulation (https://peptrackerpro.com/benefits/appetite-regulation)Metabolism (https://peptrackerpro.com/benefits/metabolism)Fat Loss (https://peptrackerpro.com/benefits/fat-loss)+3 more View Details: https://peptrackerpro.com/peptides/semaglutide \+ Compare: https://peptrackerpro.com/compare?select=semaglutide Track in App: https://app.peptrackerpro.com/?add=semaglutide ### Semax Medium Evidence A synthetic peptide derived from ACTH, studied for cognitive enhancement and neuroprotective effects. Cognition: https://peptrackerpro.com/benefits/cognition Neuroprotection: https://peptrackerpro.com/benefits/neuroprotection Mood: https://peptrackerpro.com/benefits/mood Recovery: https://peptrackerpro.com/benefits/recovery View Details: https://peptrackerpro.com/peptides/semax \+ Compare: https://peptrackerpro.com/compare?select=semax Track in App: https://app.peptrackerpro.com/?add=semax ### Sermorelin Medium Evidence A GHRH analog previously FDA-approved for growth hormone deficiency diagnosis and treatment. Muscle Growth (https://peptrackerpro.com/benefits/muscle-growth)Fat Loss (https://peptrackerpro.com/benefits/fat-loss)Sleep (https://peptrackerpro.com/benefits/sleep)Recovery (https://peptrackerpro.com/benefits/recovery)+1 more View Details: https://peptrackerpro.com/peptides/sermorelin \+ Compare: https://peptrackerpro.com/compare?select=sermorelin Track in App: https://app.peptrackerpro.com/?add=sermorelin ### Setmelanotide High Evidence A once-daily subcutaneous cyclic octapeptide melanocortin-4 receptor (MC4R) agonist, FDA-approved for several rare genetic and acquired forms of obesity that act through the leptin-melanocortin pathway. Weight Management: https://peptrackerpro.com/benefits/weight-management Appetite Regulation: https://peptrackerpro.com/benefits/appetite-regulation View Details: https://peptrackerpro.com/peptides/setmelanotide \+ Compare: https://peptrackerpro.com/compare?select=setmelanotide Track in App: https://app.peptrackerpro.com/?add=setmelanotide ### Sibeprenlimab High Evidence Sibeprenlimab (brand name VOYXACT; nonproprietary name sibeprenlimab-szsi; development code VIS649) is a humanized monoclonal antibody that binds and neutralizes APRIL (a proliferation-inducing ligand), a cytokine that drives the abnormal, antibody-producing B cells behind IgA nephropathy. By soaking up circulating APRIL with very high affinity, it lowers production of galactose-deficient IgA1 (Gd-IgA1) - the mis-glycosylated antibody whose immune complexes deposit in the kidney and cause the proteinuria and progressive damage of IgA nephropathy (IgAN). Given as a fixed 400 mg subcutaneous injection once every 4 weeks from a single-dose prefilled syringe, sibeprenlimab is designed for at-home self-administration. Originated by Visterra (acquired by Otsuka Pharmaceutical in 2018), it advanced through the Phase 2 ENVISION trial and the pivotal Phase 3 VISIONARY trial - the largest Phase 3 study conducted in IgAN - where it produced a roughly 50-54% placebo-adjusted reduction in proteinuria and signs of preserved kidney function (eGFR). On the strength of those data and an FDA Breakthrough Therapy Designation, the U.S. FDA granted VOYXACT accelerated approval in November 2025 to reduce proteinuria in adults with primary IgAN at risk of disease progression, and Otsuka began a rolling supplemental filing in 2026 seeking traditional approval on longer-term kidney-function data. Sibeprenlimab is a prescription biologic administered under medical care; it is not a supplement, nootropic, or research chemical. View Details: https://peptrackerpro.com/peptides/sibeprenlimab \+ Compare: https://peptrackerpro.com/compare?select=sibeprenlimab Track in App: https://app.peptrackerpro.com/?add=sibeprenlimab ### SLU-PP-332 Low Evidence A synthetic ERRα/β/γ pan-agonist studied as an 'exercise mimetic' for endurance, fat oxidation, and metabolic health. Energy: https://peptrackerpro.com/benefits/energy Fat Loss: https://peptrackerpro.com/benefits/fat-loss Metabolism: https://peptrackerpro.com/benefits/metabolism View Details: https://peptrackerpro.com/peptides/slu-pp-332 \+ Compare: https://peptrackerpro.com/compare?select=slu-pp-332 Track in App: https://app.peptrackerpro.com/?add=slu-pp-332 ### SNAP-8 Medium Evidence A cosmetic peptide studied for reducing the appearance of wrinkles by modulating muscle contraction signaling. Cosmetic: https://peptrackerpro.com/benefits/cosmetic Skin: https://peptrackerpro.com/benefits/skin Anti-Aging: https://peptrackerpro.com/benefits/anti-aging View Details: https://peptrackerpro.com/peptides/snap-8 \+ Compare: https://peptrackerpro.com/compare?select=snap-8 Track in App: https://app.peptrackerpro.com/?add=snap-8 ### Solbinsiran Medium Evidence An investigational subcutaneous GalNAc-conjugated small interfering RNA (siRNA) from Eli Lilly that lowers atherogenic lipids by silencing ANGPTL3 (angiopoietin-like protein 3), a liver-made brake on the fat-clearing enzymes lipoprotein lipase and endothelial lipase. By switching off ANGPTL3 production in the liver, solbinsiran simultaneously reduces both triglyceride-rich remnant particles and LDL cholesterol - the two lipid drivers of atherosclerotic cardiovascular disease. In the Phase 2 PROLONG-ANG3 trial (The Lancet, 2025; 205 adults with mixed dyslipidemia on statins), the 400 mg dose given only twice, three months apart, lowered apolipoprotein B (apoB) by a placebo-adjusted ~14% at day 180, with reductions sustained to day 270 and a ~28% fall in liver fat. Designed for infrequent dosing and built to avoid the liver toxicity that ended earlier ANGPTL3 antisense drugs, solbinsiran is positioned as the foundation for a planned Phase 3 cardiovascular outcomes program. View Details: https://peptrackerpro.com/peptides/solbinsiran \+ Compare: https://peptrackerpro.com/compare?select=solbinsiran Track in App: https://app.peptrackerpro.com/?add=solbinsiran ### Sotatercept High Evidence Sotatercept (Winrevair, sotatercept-csrk) is Merck's first-in-class activin signaling inhibitor - a recombinant ActRIIA-Fc fusion protein that acts as a ligand trap for activin A, activin B, GDF-8 (myostatin) and GDF-11. It is FDA-approved for adults with pulmonary arterial hypertension (PAH), where it improved 6-minute walk distance by 40.8 meters in the Phase 3 STELLAR trial and, in the Phase 3 ZENITH trial in high-risk patients, cut the composite risk of death, lung transplantation and PAH hospitalization by 76%. An expanded U.S. label reflecting ZENITH was approved on October 27, 2025. Cardiovascular: https://peptrackerpro.com/benefits/cardiovascular Energy: https://peptrackerpro.com/benefits/energy Rare Disease Treatment: https://peptrackerpro.com/benefits/rare-disease-treatment Disease Modification: https://peptrackerpro.com/benefits/disease-modification View Details: https://peptrackerpro.com/peptides/sotatercept \+ Compare: https://peptrackerpro.com/compare?select=sotatercept Track in App: https://app.peptrackerpro.com/?add=sotatercept ### SS-31 High Evidence A mitochondria-targeted peptide FDA-approved as FORZINITY (elamipretide) for Barth syndrome in September 2025 — the first FDA-approved mitochondrial-targeted therapeutic. Longevity: https://peptrackerpro.com/benefits/longevity Anti-Aging: https://peptrackerpro.com/benefits/anti-aging Recovery: https://peptrackerpro.com/benefits/recovery Neuroprotection: https://peptrackerpro.com/benefits/neuroprotection View Details: https://peptrackerpro.com/peptides/ss-31 \+ Compare: https://peptrackerpro.com/compare?select=ss-31 Track in App: https://app.peptrackerpro.com/?add=ss-31 ### Survodutide Medium Evidence A dual GLP-1/glucagon receptor agonist with FDA Breakthrough Therapy designation for MASH and Priority Review NDA filed February 2026. Phase 3 SYNCHRONIZE-1 reported 16.6% weight loss at 76 weeks; approval possible Q3 2026. View Details: https://peptrackerpro.com/peptides/survodutide \+ Compare: https://peptrackerpro.com/compare?select=survodutide Track in App: https://app.peptrackerpro.com/?add=survodutide ### Taldefgrobep Alfa Low Evidence A novel myostatin-activin pathway inhibitor targeting fat reduction and lean mass gain, with Phase 2 results in obesity expected H2 2026. Fat Loss (https://peptrackerpro.com/benefits/fat-loss)Muscle Preservation (https://peptrackerpro.com/benefits/muscle-preservation)Muscle Growth (https://peptrackerpro.com/benefits/muscle-growth)Body Composition (https://peptrackerpro.com/benefits/body-composition)+1 more View Details: https://peptrackerpro.com/peptides/taldefgrobep \+ Compare: https://peptrackerpro.com/compare?select=taldefgrobep Track in App: https://app.peptrackerpro.com/?add=taldefgrobep ### TB-500 Medium Evidence A naturally occurring peptide involved in cell migration and tissue repair, studied for wound healing and recovery. Recovery (https://peptrackerpro.com/benefits/recovery)Wound Healing (https://peptrackerpro.com/benefits/wound-healing)Inflammation (https://peptrackerpro.com/benefits/inflammation)Muscle Growth (https://peptrackerpro.com/benefits/muscle-growth)+1 more View Details: https://peptrackerpro.com/peptides/tb-500 \+ Compare: https://peptrackerpro.com/compare?select=tb-500 Track in App: https://app.peptrackerpro.com/?add=tb-500 ### Tesamorelin High Evidence A GHRH analog FDA-approved for reducing visceral fat in HIV-associated lipodystrophy. Fat Loss: https://peptrackerpro.com/benefits/fat-loss Muscle Growth: https://peptrackerpro.com/benefits/muscle-growth Metabolism: https://peptrackerpro.com/benefits/metabolism Anti-Aging: https://peptrackerpro.com/benefits/anti-aging View Details: https://peptrackerpro.com/peptides/tesamorelin \+ Compare: https://peptrackerpro.com/compare?select=tesamorelin Track in App: https://app.peptrackerpro.com/?add=tesamorelin ### Thymalin Low Evidence A thymic peptide preparation studied for immune system rejuvenation and age-related immune decline. Immune Support: https://peptrackerpro.com/benefits/immune-support Longevity: https://peptrackerpro.com/benefits/longevity Anti-Aging: https://peptrackerpro.com/benefits/anti-aging View Details: https://peptrackerpro.com/peptides/thymalin \+ Compare: https://peptrackerpro.com/compare?select=thymalin Track in App: https://app.peptrackerpro.com/?add=thymalin ### Thymosin Alpha-1 High Evidence A thymic peptide approved in some countries for immune modulation, studied for viral infections and cancer adjunct therapy. Immune Support: https://peptrackerpro.com/benefits/immune-support Longevity: https://peptrackerpro.com/benefits/longevity Inflammation: https://peptrackerpro.com/benefits/inflammation View Details: https://peptrackerpro.com/peptides/thymosin-alpha-1 \+ Compare: https://peptrackerpro.com/compare?select=thymosin-alpha-1 Track in App: https://app.peptrackerpro.com/?add=thymosin-alpha-1 ### Tirzepatide High Evidence A dual GIP/GLP-1 receptor agonist FDA-approved for type 2 diabetes, weight management, and MASH with liver fibrosis. View Details: https://peptrackerpro.com/peptides/tirzepatide \+ Compare: https://peptrackerpro.com/compare?select=tirzepatide Track in App: https://app.peptrackerpro.com/?add=tirzepatide ### Trevogrumab Medium Evidence Trevogrumab (REGN1033) is an investigational fully human anti-myostatin (anti-GDF8) monoclonal antibody from Regeneron being tested as a lean-mass-sparing add-on to semaglutide in the Phase 2 COURAGE obesity trial; adding it to semaglutide prevented roughly half of the ~33% of GLP-1-induced weight loss that normally comes from muscle, and the semaglutide + trevogrumab + garetosmab triplet reached 13.4% weight loss at 26 weeks with only ~7.4% of that loss from lean mass. Muscle Preservation: https://peptrackerpro.com/benefits/muscle-preservation Body Composition: https://peptrackerpro.com/benefits/body-composition Fat Loss: https://peptrackerpro.com/benefits/fat-loss Weight Management: https://peptrackerpro.com/benefits/weight-management View Details: https://peptrackerpro.com/peptides/trevogrumab \+ Compare: https://peptrackerpro.com/compare?select=trevogrumab Track in App: https://app.peptrackerpro.com/?add=trevogrumab ### Trofinetide High Evidence A twice-daily oral peptide analog of the IGF-1 tripeptide glycine-proline-glutamate (GPE) that is the first and only medicine approved to treat Rett syndrome. Marketed by Acadia Pharmaceuticals as Daybue, trofinetide does not correct the underlying MECP2 mutation; instead it works on the downstream consequences - it is thought to restore synaptic signaling, dampen neuroinflammation, and normalize overactive microglia and astrocytes, improving neurobehavioral symptoms. It won FDA approval in March 2023 for adults and children 2 years and older. In late 2025 the FDA cleared a dye- and preservative-free powder formulation (Daybue STIX, broadly available in April 2026), and in June 2026 the EMA's CHMP adopted a positive opinion recommending European authorization. Neuroprotection: https://peptrackerpro.com/benefits/neuroprotection View Details: https://peptrackerpro.com/peptides/trofinetide \+ Compare: https://peptrackerpro.com/compare?select=trofinetide Track in App: https://app.peptrackerpro.com/?add=trofinetide ### Trontinemab Medium Evidence An investigational, brain-penetrant anti-amyloid antibody from Roche/Genentech that uses the proprietary 'Brainshuttle' transferrin-receptor delivery system to reach the brain far more efficiently than conventional antibodies. Trontinemab (development codes RG6102 / RO7126209) is a 2+1 bispecific molecule: it fuses the amyloid-beta-clearing antibody gantenerumab to a fragment that grabs transferrin receptor 1 (TfR1) on blood-brain-barrier cells, hitching a ride into the brain via the same receptor-mediated transport that carries iron. That shuttle lets a low intravenous dose clear amyloid plaques rapidly and deeply while triggering strikingly little of the brain swelling and micro-bleeding (ARIA) that limits approved anti-amyloid drugs. In the Phase Ib/IIa Brainshuttle AD study (NCT04639050), the 3.6 mg/kg dose removed roughly 107 centiloids of amyloid after 28 weeks, driving about 91-92% of participants below the amyloid-positivity threshold (24 centiloids) - with ARIA-E seen in fewer than 5% of participants, well below the ~13% reported for lecanemab and ~24% for donanemab. On the strength of those data, Roche launched two identical pivotal Phase 3 trials - TRONTIER 1 and TRONTIER 2 - in early symptomatic Alzheimer's disease (about 1,600 patients across 18 countries, begun in 2025), and at the 2026 Alzheimer's Association International Conference (AAIC) in London it unveiled PrevenTRON, a Phase 3 prevention trial in 1,600 cognitively unimpaired people at high risk (elevated plasma p-tau217). Trontinemab is a prescription-stage investigational biologic - it is not approved anywhere and is not a supplement or research chemical. View Details: https://peptrackerpro.com/peptides/trontinemab \+ Compare: https://peptrackerpro.com/compare?select=trontinemab Track in App: https://app.peptrackerpro.com/?add=trontinemab ### UBT251 Medium Evidence A GLP-1/GIP/glucagon triple receptor agonist in Phase 2 development for type 2 diabetes and obesity, competing with retatrutide in the triple-agonist space. View Details: https://peptrackerpro.com/peptides/ubt251 \+ Compare: https://peptrackerpro.com/compare?select=ubt251 Track in App: https://app.peptrackerpro.com/?add=ubt251 ### VIP Medium Evidence A neuropeptide with broad neuroimmune functions, studied for inflammatory conditions and nerve repair. Nerve Repair: https://peptrackerpro.com/benefits/nerve-repair Inflammation: https://peptrackerpro.com/benefits/inflammation Immune Support: https://peptrackerpro.com/benefits/immune-support Neuroprotection: https://peptrackerpro.com/benefits/neuroprotection View Details: https://peptrackerpro.com/peptides/vip \+ Compare: https://peptrackerpro.com/compare?select=vip Track in App: https://app.peptrackerpro.com/?add=vip ### VK2735 Medium Evidence An investigational oral and injectable GLP-1/GIP dual agonist showing 12.2% oral weight loss at 13 weeks at ECO 2026 and 14.7% injectable weight loss, with Phase 3 VANQUISH trials fully enrolled. View Details: https://peptrackerpro.com/peptides/vk2735 \+ Compare: https://peptrackerpro.com/compare?select=vk2735 Track in App: https://app.peptrackerpro.com/?add=vk2735 ### Volenrelaxin Medium Evidence An investigational, once-weekly injectable long-acting analogue of the human hormone relaxin-2 from Eli Lilly, engineered as a selective agonist of the relaxin family peptide receptor 1 (RXFP1) and studied for chronic kidney disease and heart failure. Natural relaxin is a peptide hormone with vasodilatory, anti-inflammatory and anti-fibrotic effects, but it clears from the body within hours; volenrelaxin fuses relaxin-2 to an albumin-binding VHH (single-domain antibody) fragment that latches onto serum albumin to extend its half-life beyond ~40 hours in animals, allowing once-weekly subcutaneous dosing. In a randomized Phase 1 trial it increased effective renal plasma flow (a marker of kidney perfusion) by roughly 44-50% versus placebo, supporting development in chronic kidney disease and heart failure. However, in the Phase 2 RELAXIN-LA trial (n=332) in people with worsening heart failure with preserved ejection fraction (HFpEF), the program hit a wall: although the lowest 25 mg dose modestly improved the primary imaging endpoint (left atrial reservoir strain), the pooled higher doses were associated with WORSENING congestion - rising NT-proBNP, more estimated plasma volume, and a numerically higher rate of heart-failure hospitalizations - prompting the sponsor to stop the trial early, and the authors concluded the data do NOT support further evaluation of volenrelaxin in worsening HFpEF. Volenrelaxin is an investigational prescription-stage medicine studied only in clinical trials - it is not approved anywhere and is not a supplement or research chemical. Cardiovascular: https://peptrackerpro.com/benefits/cardiovascular Kidney Health: https://peptrackerpro.com/benefits/kidney-health Inflammation: https://peptrackerpro.com/benefits/inflammation View Details: https://peptrackerpro.com/peptides/volenrelaxin \+ Compare: https://peptrackerpro.com/compare?select=volenrelaxin Track in App: https://app.peptrackerpro.com/?add=volenrelaxin ### Vosoritide High Evidence A once-daily subcutaneous peptide (a 39-amino-acid analog of C-type natriuretic peptide, CNP) that is the first approved medicine to increase linear growth in children with achondroplasia. Marketed by BioMarin as Voxzogo, it works one step downstream of the overactive FGFR3 receptor that causes achondroplasia: by binding natriuretic peptide receptor-B (NPR-B), it dampens FGFR3's braking signal on the growth plate and lets cartilage cells proliferate and mature normally. First FDA-approved in November 2021 for children 5 and older with open growth plates, its label was expanded in 2023 to cover children under 5 (all ages with open growth plates). In 2026 BioMarin reported new long-term and early-treatment data and advanced a once-weekly successor CNP peptide, BMN 333. Bone Growth: https://peptrackerpro.com/benefits/bone-growth View Details: https://peptrackerpro.com/peptides/vosoritide \+ Compare: https://peptrackerpro.com/compare?select=vosoritide Track in App: https://app.peptrackerpro.com/?add=vosoritide ### Vutrisiran High Evidence An approved, quarterly (once-every-three-months) subcutaneous GalNAc-conjugated small interfering RNA (siRNA) from Alnylam that treats transthyretin-mediated (ATTR) amyloidosis by silencing the TTR gene in the liver. Transthyretin is a liver-made transport protein that can misfold and pile up as amyloid deposits in nerves and, critically, the heart; vutrisiran uses RNA interference (RNAi) to degrade both mutant and wild-type TTR messenger RNA before the protein is made, lowering circulating TTR by roughly 80% and starving the amyloid of its raw material. Marketed as Amvuttra, it was first FDA-approved in June 2022 for the polyneuropathy of hereditary ATTR amyloidosis (HELIOS-A), and in March 2025 the FDA expanded the label to ATTR cardiomyopathy (ATTR-CM) of wild-type or hereditary disease - making vutrisiran the first RNAi therapeutic shown to reduce cardiovascular death and cardiovascular events, on the strength of the HELIOS-B outcomes trial. It shares the exact GalNAc-siRNA delivery platform that underlies the cardiometabolic RNAi medicine inclisiran and the investigational agents olpasiran, lepodisiran, zerlasiran, zilebesiran, zodasiran, solbinsiran and plozasiran, and it is the direct successor to Alnylam's earlier intravenous TTR siRNA patisiran (Onpattro). View Details: https://peptrackerpro.com/peptides/vutrisiran \+ Compare: https://peptrackerpro.com/compare?select=vutrisiran Track in App: https://app.peptrackerpro.com/?add=vutrisiran ### WVE-007 Low Evidence WVE-007 is Wave Life Sciences' investigational GalNAc-conjugated siRNA that silences the liver gene INHBE to lower the hepatokine Activin E, aiming to produce muscle-sparing fat loss. In the Phase 1 INLIGHT trial a single subcutaneous dose reduced visceral and total fat while preserving or increasing lean mass, with durable target knockdown that could support once- or twice-yearly dosing. View Details: https://peptrackerpro.com/peptides/wve-007 \+ Compare: https://peptrackerpro.com/compare?select=wve-007 Track in App: https://app.peptrackerpro.com/?add=wve-007 ### Zenagamtide Low Evidence A unimolecular GLP-1 and amylin receptor co-agonist developed by Novo Nordisk, available in both subcutaneous and oral formulations, with Phase 2 data showing up to 24.3% weight loss and Phase 3 AMAZE trials initiated in 2026. Weight Management: https://peptrackerpro.com/benefits/weight-management Metabolism: https://peptrackerpro.com/benefits/metabolism Glycemic Control: https://peptrackerpro.com/benefits/glycemic-control Appetite Regulation: https://peptrackerpro.com/benefits/appetite-regulation View Details: https://peptrackerpro.com/peptides/zenagamtide \+ Compare: https://peptrackerpro.com/compare?select=zenagamtide Track in App: https://app.peptrackerpro.com/?add=zenagamtide ### Zerlasiran Medium Evidence An investigational, long-acting injectable small interfering RNA (siRNA) from Silence Therapeutics that lowers lipoprotein(a) [Lp(a)] by more than 80% by silencing the LPA gene in the liver. Dosed only every 16–24 weeks, it produced durable ~90% reductions in its Phase 2 ALPACAR-360 trial (published in JAMA, 2024); as of 2026 the company is seeking a partner before starting its Phase 3 cardiovascular outcomes study. View Details: https://peptrackerpro.com/peptides/zerlasiran \+ Compare: https://peptrackerpro.com/compare?select=zerlasiran Track in App: https://app.peptrackerpro.com/?add=zerlasiran ### Zilebesiran Medium Evidence An investigational subcutaneous GalNAc-conjugated small interfering RNA (siRNA) from Alnylam Pharmaceuticals and Roche/Genentech that lowers blood pressure by silencing angiotensinogen (AGT), the single upstream precursor of the renin-angiotensin-aldosterone system (RAAS). Designed for dosing as infrequently as once or twice a year, it is the first RNА interference (RNAi) therapeutic developed for hypertension. In Phase 2 KARDIA-1 and KARDIA-2 trials it produced durable, clinically meaningful reductions in systolic blood pressure sustained for up to 6 months from a single dose, and in 2025 it advanced into the large Phase 3 ZENITH cardiovascular outcomes trial. Cardiovascular: https://peptrackerpro.com/benefits/cardiovascular Disease Modification: https://peptrackerpro.com/benefits/disease-modification View Details: https://peptrackerpro.com/peptides/zilebesiran \+ Compare: https://peptrackerpro.com/compare?select=zilebesiran Track in App: https://app.peptrackerpro.com/?add=zilebesiran ### Ziltivekimab Medium Evidence An investigational, fully human monoclonal antibody that neutralizes the pro-inflammatory cytokine interleukin-6 (IL-6) to test whether lowering vascular inflammation - independently of cholesterol - can prevent heart attacks, strokes and cardiovascular death. Given as a low-volume, once-monthly 15 mg subcutaneous injection (half-life ~57 days), ziltivekimab was originally developed by Corvidia Therapeutics and acquired by Novo Nordisk in 2020 for up to $2.1 billion. It is the flagship clinical test of the 'residual inflammatory risk' hypothesis that grew out of the CANTOS trial of the IL-1 beta antibody canakinumab: the idea that many high-risk patients keep having cardiovascular events because of ongoing inflammation (marked by high-sensitivity C-reactive protein, hsCRP) even when LDL cholesterol is well controlled. In the Phase 2 RESCUE trial ziltivekimab cut hsCRP by up to ~92%, and it advanced into three large Phase 3 cardiovascular outcomes trials - ZEUS, HERMES and ARTEMIS. On July 31, 2026, Novo Nordisk announced that the pivotal ZEUS trial (>6,300 patients with atherosclerotic cardiovascular disease, chronic kidney disease and inflammation) MISSED its primary endpoint: despite clear target engagement (large falls in free IL-6 and hsCRP), ziltivekimab did not reduce major adverse cardiovascular events versus placebo (hazard ratio 0.99, 95% CI 0.88-1.11). The heart-failure trial HERMES and the post-heart-attack trial ARTEMIS continue, with readouts expected in the first half of 2027. Ziltivekimab is a prescription-stage investigational biologic - it is not approved anywhere and is not a supplement or research chemical. Inflammation: https://peptrackerpro.com/benefits/inflammation Cardiovascular: https://peptrackerpro.com/benefits/cardiovascular Kidney Health: https://peptrackerpro.com/benefits/kidney-health Cholesterol Management: https://peptrackerpro.com/benefits/cholesterol-management View Details: https://peptrackerpro.com/peptides/ziltivekimab \+ Compare: https://peptrackerpro.com/compare?select=ziltivekimab Track in App: https://app.peptrackerpro.com/?add=ziltivekimab ### Zilucoplan High Evidence A self-administered, once-daily subcutaneous macrocyclic peptide that inhibits complement component 5 (C5), FDA- and EMA-approved for anti-AChR-positive generalized myasthenia gravis. Immune Modulation: https://peptrackerpro.com/benefits/immune-modulation Neuromuscular Function: https://peptrackerpro.com/benefits/neuromuscular-function View Details: https://peptrackerpro.com/peptides/zilucoplan \+ Compare: https://peptrackerpro.com/compare?select=zilucoplan Track in App: https://app.peptrackerpro.com/?add=zilucoplan ### Zodasiran Medium Evidence An investigational subcutaneous GalNAc-conjugated small interfering RNA (siRNA) from Arrowhead Pharmaceuticals that lowers atherogenic lipids by silencing ANGPTL3 (angiopoietin-like protein 3), a liver-made regulator of fat metabolism. By switching off ANGPTL3 production, zodasiran deeply reduces triglycerides, remnant cholesterol and LDL cholesterol through a pathway that does not depend on the LDL receptor - making it especially relevant for people, such as those with homozygous familial hypercholesterolemia (HoFH), whose LDL receptors barely work. In the Phase 2b ARCHES-2 trial (NEJM 2024) it produced durable, dose-dependent reductions in triglycerides, remnant cholesterol and ANGPTL3, and in the Phase 2 GATEWAY study it lowered LDL cholesterol by about 40% in HoFH. It is now in the Phase 3 YOSEMITE trial in HoFH, which completed enrollment in July 2026. View Details: https://peptrackerpro.com/peptides/zodasiran \+ Compare: https://peptrackerpro.com/compare?select=zodasiran Track in App: https://app.peptrackerpro.com/?add=zodasiran ### Zosurabalpin Medium Evidence A first-in-class tethered macrocyclic peptide antibiotic that kills carbapenem-resistant Acinetobacter baumannii (CRAB) by blocking the bacterium's lipopolysaccharide (LPS) transporter, now advancing into a global Phase 3 trial. View Details: https://peptrackerpro.com/peptides/zosurabalpin \+ Compare: https://peptrackerpro.com/compare?select=zosurabalpin Track in App: https://app.peptrackerpro.com/?add=zosurabalpin Track Your Research with PepTracker Pro Try the Free App → (https://app.peptrackerpro.com/)